Circulating Fibrocytes, their role in renal fibrosis and molecular pathways involved. Possible biomarkers of fibrogenesis in chronic kidney disease by Fici, Pietro
 ALMA MATER STUDIORUM - UNIVERSITÀ DI BOLOGNA 
 
DOTTORATO DI RICERCA IN 
SCIENZE MEDICHE SPECIALISTICHE  
 
Ciclo XXVI 
 
 
 
Settore Concorsuale di afferenza: 06/D2 
Settore Scientifico disciplinare: MED/14 
 
 
 
Circulating Fibrocytes, their role in renal fibrosis and molecular 
pathways involved. Possible biomarkers of fibrogenesis in chronic 
kidney disease 
 
 
 
Presentata da: Dott. Pietro Fici 
 
 
 
Coordinatore Dottorato      Relatore 
Prof. Sandro Mattioli       Prof. Gaetano La Manna 
         Correlatore 
         Dott. Wainer Zoli 
 
 
Esame finale anno 2014 
2 
  
3 
Summary 
 
Abstract .................................................................................................................................. 5 
Background ............................................................................................................................ 6 
1. Circulating Fibrocytes .................................................................................................... 8 
1.1. Origin and phenotypic characteristics ............................................................................ 9 
1.2. Differentiation .............................................................................................................. 10 
1.3. Homing ......................................................................................................................... 12 
1.4. Function ........................................................................................................................ 13 
1.5. Fibrocytes in chronic inflammation and fibrosis .......................................................... 15 
1.5.1. In Aging ................................................................................................................... 16 
1.5.2. In autoimmunity disorders ....................................................................................... 17 
1.5.3. In cardiovascular diseases ........................................................................................ 18 
1.5.4. In Asthma and Idiopatic Pulmonary Fibrosis .......................................................... 19 
1.5.5. In liver fibrosis ......................................................................................................... 20 
1.5.6. In skin and systemic fibrosis .................................................................................... 21 
1.5.7. Fibrocytes in other chronic inflammation and cancer ............................................. 22 
2. Chronic Kidney Disease and Renal Fibrosis ................................................................ 24 
2.1. CKD epidemiology, etiology and classification ........................................................... 24 
2.2. CKD and kidney damage progression .......................................................................... 27 
2.3. Renal Fibrosis ............................................................................................................... 29 
3. Role of Circulating Fibrocytes into Renal Fibrosis ...................................................... 37 
Experimental Study ............................................................................................................. 39 
4. Aims ............................................................................................................................. 39 
5. Materials and Methods ................................................................................................. 40 
5.1. Samples......................................................................................................................... 40 
5.2. Sample collection systems ............................................................................................ 41 
5.3. Enrichment methods ..................................................................................................... 41 
5.4. Cytometry analysis ....................................................................................................... 42 
4 
5.5. Cell cultures and in vitro differentiation assay ............................................................. 43 
5.6. Gene expression assays ................................................................................................ 44 
5.7. Statistical analysis ........................................................................................................ 45 
6. Results .......................................................................................................................... 46 
6.1. Enrichment protocols.................................................................................................... 47 
6.2. Circulating fibrocytes detection by flow cytometry analysis ....................................... 47 
6.3. Cell cultures and cell count differentiated fibrocytes ................................................... 48 
6.4. Gene Expression analysis of principal fibrocyte markers ............................................ 48 
7. Discussion..................................................................................................................... 50 
8. Conclusion and futures ................................................................................................. 53 
Bibliography ........................................................................................................................ 54 
Sitography ............................................................................................................................ 67 
 
  
5 
Abstract 
Circulating Fibrocytes (CFs) are bone marrow-derived mesenchymal progenitor cells that 
express a similar pattern of surface markers related to leukocytes, hematopoietic progenitor 
cells and fibroblasts. CFs precursor display an ability to differentiate into fibroblasts and  
Myofibroblasts, as well as adipocytes. 
Fibrocytes have been shown to contribute to tissue fibrosis in the end-stage renal disease 
(ESRD), as well as in other fibrotic diseases, leading to fibrogenic process in other organs 
including lung, cardiac, gut and liver. This evidence has been confirmed by several 
experimental proofs in mice models of kidney injury. 
In the present study, we developed a protocol for the study of CFs, by using peripheral 
blood monocytes cells (PBMCs) samples collected from healthy human volunteers. 
Thanks to a flow cytometry method, in vitro culture assays and the gene expression assays, 
we are able to study and characterize this CFs population. Moreover, results confirmed that 
these approaches are reliable and reproducible for the investigation of the circulating 
fibrocytes population in whole blood samples.  
Our final aim is to confirm the presence of a correlation between the renal fibrosis 
progression, and the different circulating fibrocyte levels in Chronic Kidney Disease 
(CKD) patients. Thanks to a protocol study presented and accepted by the Ethic Committee 
we are continuing the study of CFs induction in a cohort of sixty patients affected by CKD, 
divided in three distinct groups for different glomerular filtration rate (GFR) levels, plus a 
control group of thirty healthy subjects. Ongoing experiments will determine whether  
circulating fibrocytes represent novel biomarkers for the study of CKD progression, in the 
early and late phases of this disease.  
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Background  
Human body ability to replace damaged or dead cells and repair tissue at the end of 
inflammatory process is essential for survival. Wound healing process has the function to 
restore the architecture and allow the recovery of the physiological functions of the 
damaged tissue. However, tissue repair could be result into two distinct processes, both 
involved into the repair processes. 1) the total tissue regeneration, namely the replacement 
of damaged cells with tissue-specific cells, restoring the physiological functions and not 
leaving signs of the previous damage; 2) either to fibrosis, where the chronic injury of the 
tissue induce hyperactivation of inflammatory cells and an excessive connective tissue 
deposition, leading to a permanent fibrotic scar formation and the loss of the physiological 
functions of the organs involved. The complete regeneration of damaged tissues occurs 
exclusively in the fetus but the reasons are still poorly understood, (Miller et al., 1973). In 
adulthood healing is more difficult, most of all in chronic disease. The body then tries to 
repair tissue damage by replacement of parenchymal cells and connective tissue. Over time 
these results in fibrosis and scarring. Fibrosis is the end-stage of chronic inflammatory 
reactions induced by a variety of stimuli as: persistent infection, autoimmune reaction 
allergic response, chemical insult, radiation and/or other tissue injury. It is characterized by 
the development of excessive extracellular matrix (ECM) production, cellular apoptosis 
and inflammatory cells infiltration, sustained by a pro-inflammatory microenvironment. 
(Wynn TA., 2008). The primary source of matrix synthesis are the myofibroblasts, which 
are fibroblast activated cells that may derive by local activated fibroblast and/or through 
the differentiation to activated phenotype of other cells involved into the fibrosis.. These 
are able to repair tissue damage by secreting extracellular matrix and develop contractile 
forces through their capacity to synthesize α-smooth muscle actin (α-SMA), such as to 
orchestrate the process by secreted cytokines and chemokins (Eddy AA., 2013). 
Fibrocytes, a bone-marrow derived cells, are leading actors of this process and may have 
both beneficial and detrimental effects on health. These can regulated the innate and 
adaptive immune response, by the expression and secretion of a variety of chemokines and 
growth factors. Also, they promote wound healing both directly and by secreting factors 
that activate residence fibroblast and other fibrocytes. (Bucala et al., 2007; Pilling et al., 
2012)  
As well in the kidney, regardless of etiology, the ultimate outcome of chronic injury is 
interested by a fibrogenic process. This is the final renal injury state as known as end-stage 
of renal disease (Risdon R.A. et al. 1968).It result into fibrotic plaques formation in the 
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tissue interstitium that compromise kidney function and result into tubulointerstitial injury, 
(Kisseleva et al., 2008). 
Fibrocytes have been shown to contribute to tissue fibrosis in the end-stage of renal 
disease, as well as in other fibrotic disease, which appear to involved in other organ 
fibrogenic process including: lung, cardiac, gut and liver. This has been confirmed by 
different experimental results on different mice models of injury. 
Moreover, the levels of circulating fibrocytes recruitment into the tissue damages correlate 
inversely whit the pathologic progression of the diseases (Wada T. et al., 2011), as 
revealed by different data by in vivo and in vitro studies of idiopatic pulmonary fibrosis 
and chronic kidney disease. Circulating fibrocytes are considered one of the principal 
source of active fibroblast/myofibroblasts, among the non-residents cells, into the kidney 
injury (about 35%), (LeBleu et al., 2013).  
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1. Circulating Fibrocytes 
Circulating fibrocytes are bone marrow-derived mesenchymal cells that co-express 
haematopoietic stem cell antigens, markers of monocytes lineage and fibroblast products. 
Although their biology has come under study recently, the description of a fibrocyte-like 
cell population was first proposed more than 150 years ago (Cohnheim J. et al., 1867). 
However, it was not until 1994 that the fibrocytes were first described in a wound-healing 
chamber experiments, as a subpopulation of leucocytes that accumulate at site of tissue 
injury and show haematopoietic and progenitor cell markers, CD45 and CD34 
respectively, and extracellular matrix (ECM) protein (collagen type I-IV), together. Also, 
these cells present in the wound exudates, were observed to adopt a morphology spindle 
shaped typical of fibroblast when adherent (Bucala et al., 1994). It has been proposed that 
fibrocytes may be a transitional stage between a monocytes and a fibroblast (Reilkoff R.A. 
et al., 2011).  
Fibrocytes, as high plastic cell population able to adopt the phenotype of macrophages, 
fibroblast and activates myofibroblast, seem to contribute to both tissue injury repair and 
remodeling process through a series of important mechanisms (Chesney et al., 1997). They 
constitutively produce extracellular matrix components (collagen, vimentin and fibrin) as 
well as ECM-modifying enzymes, as metalloproteases (MMPs) . They can further 
differentiate into myofibroblast, under permissive micro-environmental condition, with 
expression α-SMA, favoring the contraction for the closure of the wound (Metz, 2003), 
also by the induction of angiogenesis (Hartlapp et al., 2001). Moreover, these produce 
cytokines, chemokines and growth factors that further stimulate fibroblastic hyperplasia 
(Chesney et al., 1998). In the setting of persisted injury that cause ongoing immune 
activation and impeded repair, fibrocytes increase the local inflammatory and pro-fibrotic 
cell populations, leading to formation of excessive fibrous connective tissue that disrupt 
normal tissue function also in the early phases of healing process (Bucala et al., 1994; 
Reilkoff R.A. et al., 2011). The functional relationship between fibrocytes and the related 
effector cell population of macrophages and fibroblasts has not yet been fully explicated 
and specific markers for distinguishing them don’t exist. The potential for overlap in the 
identification and function of these different cells and a lack of the subtle differences 
between them might impede a full understanding of the role of fibrocytes in chronic 
inflammation.  
Normally, circulating fibrocytes comprise only a small fraction of circulating leucocytes in 
healthy humans, comprise between 0,1-1% of them. Increased number of these are present 
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in human pathologies that are characterized by both chronic macrophage-derived 
inflammation and persisted fibroblast activation. Such disorders include pulmonary 
parenchymal airway disease (Phillips et al., 2004; Keely et al. rew 2009), cardiovascular 
disease (Medbury et al., 2008), pulmonary hypertension (Nikam et al., 2010), autoimmune 
disorders (Galligan et al., 2010) and metastatic tumor (Herzog et al. 2010). Furthermore, 
fibrocytes are implicates in the even normal aging, and development of tissue fibrosis 
including liver, heart, lung and kidney fibrosis, as indicated by animal modeling and some 
humans studies (Reilkoff R.A. et al., 2011). 
 
1.1. Origin and phenotypic characteristics 
Expression of haematopoietic stem cell/progenitor marker CD34, the leukocyte common 
antigen CD45 and several markers of the monocyte lineage, concomitantly to fibroblast 
markers (collagen and vimentin ) suggested the bone marrow-origin of fibrocytes. 
Bucala and colleges indicated fibrocytes as circulating population of non-erythrocyte cells 
on the basis of the isolation of these from culture of peripheral blood mononuclear cells, 
but additional experiments from the same group and other investigator revealed that human 
fibrocytes may not be present in the peripheral blood and that may originate from 
circulating precursor (Bellini A et al. 2007). It is a monocytes “not-exclusive” precursor 
and it able to differentiate into different cell population as adipocytes, chondrocytes, 
osteoblast as well as myofibroblast (Choi Y.H. et al, 2010; Quan T.E. et al., 2004; Hong 
K.M. et al., 2005). It has been proposed that fibrocytes may be a transitional stage between 
monocytes and tissue fibroblast (Reilkoff R.A. et al., 2011). 
Fibrocytes mature from a subpopulation of CD14
+
peripheral blood mononuclear cells that 
express the receptor for the Fc portion of immunoglobulin G (IgG) FcγRI (CD64) and 
FcγRII (CD32) and do not express FcγRIII (CD16), (Pilling et al., 2003; Pilling et al., 
2006; Haudeck S.B. et al, 2006). Circulating fibrocytes precursors may be present in a 
small fraction of the CD14
+
/CD16
-
 subset of human mononuclear cell that bear C-C motif 
chemokine receptor (CCR)-2 on their surface. This subset constitutes an immature 
subpopulation of cells that are normally present in the circulation and have been termed 
“inflammatory” monocytes. While in health stage, they likely serve to replenish the tissue-
resident cells, during an inflammatory process they are released in high number from bone 
marrow into the peripheral blood and directly migrate to inflamed site (Gordon S. et al., 
2005). In experimental murine models, bone marrow from enhanced green fluorescent 
protein (EGFP) transgenic mice was transplanted into normal mice. The analysis revealed 
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that the injured skin of this murine model contain numerous EGFP+ with circulating 
fibrocytes futures, thus validating their hematopoietic origin (Fathke C. etal., 2004). 
Consisted with this, other studies showed that human fibrocytes express several 
haematopoietic cell markers, including CD45RO and Lymphocytes Specific Protein (LSP)-
1. Also, there express several CCRs and CXC chemokine receptors (CXCRs), including 
CCR7 and CXCR4, such as haematopoietic progenitors (Pilling et al., 2003; Abe et al., 
2001). More data confirm that fibrocytes derive from precursor of the monocyte lineage. It 
is supported by the evidence that these cells express the major histocompatibility complex 
class I and class II (MHC I and II); co-stimulatory molecules CD80 and CD86, exhibit 
antigen-presenting activity and active both CD4
+
and CD8
+ 
T lymphocytes. Moreover, they 
lack the adhesion molecules CD11b, CD11c and CD11d (Chesney J., et al, 1997; Belmelli 
C., et al., 2005). Circulating and cultured fibrocytes also express CD34, often expressed by 
pluripotent cells, that discriminate these from tissue macrophages and fibroblasts. 
Otherwise, they express collagens and glycosaminoglycans as fibroblasts (Reilkoff R.A. et 
al., 2011). 
Human fibrocytes probably represent the obligate intermediate stage of differentiation of 
one of these precursors of the monocytes lineage into mature fibroblast and myofibroblast 
at the tissue sites (Bellini A et al. 2007). 
The combination of collagen production and expression of CD45 or one of the 
haematopoietic (CD34) or myeloid antigens (CD11b) is considered as a sufficient criterion 
to discriminate fibrocytes from leukocytes, dendritic cells, endothelial cells and tissue-
resident fibroblasts in vitro and in vivo (Herzog E.L. et al., 2010). Moreover, an important 
study revealed that markers as CD45RO, 25F9 ed S100A8/A9 could help to distinguish 
monocyte-derived fibrocytes from monocytes macrophage and fibroblast, by culture 
differentiation experiments (Pilling D. et al., 2009). However, the misclassification of 
fibrocytes in studies of culture cells and tissue could be due for an overlap in markers 
expression. In this setting, morphological assessment becomes useful. The spindle-shaped 
morphology adopted by adherent fibrocytes distinguishes them from macrophages, which 
are more spherical and haven’t the haematopoietic cell and inflammatory markers that are 
expressed by fibrocytes (Pilling D. et al., 2009) 
 
1.2. Differentiation 
Initial observation and laboratory investigations showed the development of fibrocytes 
from peripheral blood mononuclear cells after 10-14 days of culture in media containing 
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high concentrations of serum. Subsequent, other investigations revealed that, if cultured in 
serum-free media, cells with fibrocytes futures appeared after only 3 days (Pilling D. et al., 
2003; Pilling D. et al., 2008).  
Circulating fibrocytes precursor derived from a subpopulation of CD14
+
 circulating 
monocytes,  which comprehend a mixture of multipotent precursor able to differentiate 
into a number of cells other than macrophages and dendritic cells (i.e. myoblast, osteoblast, 
chondrocytes, adypocytes, etc.) under certain permissive condition. The development of 
fibrocytes and these differentiation into mature mesenchymal cells is regulated by different 
signals through Fcγ receptor (FcγR) and is augmented by enrichment monocytes for 
expression of pro-inflammatory markers such us CD11b, CD115 and GR1 (Bellini et al., 
2007). Studies showed that circulating fibrocytes can be too isolated in vitro in serum-
containing conditioning factors as tissue growth factor (TGF)-β or interleukins (ILs), 
although the presence of serum (i.e. such as may be encountered during in vivo injury) 
produces a more pro-inflammatory phenotype. 
Fibrocytes development is amplified by fibrogenic cytokines signals such us platelet-
derived growth factor (PDGF), interleukin (IL)-4 and IL-13. Despite, other pro-
inflammatory cytokines inhibit this phenomenon, such as showed by interferon (IFN)-γ, 
tumor necrosis factor (TNF), IL12 culture treatment and serum amyloid P (SAP) also by 
innate immune stimulation with Toll-like receptor (TLR)-2 agonist (Bellini et al 2007). 
This was highlighted by in vitro studies by direct contact between T lymphocytes 
(inflammation regulatory cell) and CD14
+
monocytes in co-culture assays and by their 
direct stimulation with fibrogenic or inflammatory factors, described above (Shao D.D. et 
al., 2008).  
Fibrocytes are immature mesenchymal cells that do not produce large amounts of collagens 
or other ECM components until they differentiate into mature fibroblast and myofibroblast. 
Once fibrocytes have completed their maturation from monocyte precursors, further 
differentiation into cells ultrastructurally and phenotipically similar to mature fibroblast 
and myofibroblast is promoted by stimulation with TGF-β and endothelin (ET)- 1 (Bellini 
et al 2007). Treatment of primary culture cells of circulating fibrocytes precursor with 
TGF-β and ET-1 induce much more collagens and fibronectin than untreated cells, express 
the myofibroblast marker as α-SMA and downregulate the expression of CD34 and CD45, 
and of the other lymphocytes markers(Schmidt et al., 2003); same results are showed into 
murin model in vivo(Murray L.A. et al., 2011). 
These data indicate that fibrocytes differentiation in both culture and disease model 
decreases under conditions that perpetuate inflammation and tissue injury and increase 
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under condition that promote wound-healing and tissue remodeling. Balance between 
inflammatory cytokine and profibrotic factors, TGF-β in primis, likely determines the 
ultimate fate of fibrocytes (Galligan et al., 2013).  
 
1.3. Homing  
Initial observations of fibrocytes recruitment to wound side were found to be due to 
specific chemokine-chemokine receptor interactions. Namely, it was shown that fibrocytes 
migrate to wounds in response to secondary lymphoid chemokine (SLC) also known as 
chemochine (C-C)-ligands 21 (CCL21), which is the ligand for (C-C) receptor CCR7. It 
was observed in a murin model of wound-healing assay (Abe R. et al., 2001). Afterward, 
other chemokine expression profile has revealed other chemokine receptors on the surface 
of fibrocytes, and vice versa, through the study of inflametion disease and associated 
disease models (Blakaja et al., 2012). Chemokines play an important role in the regulation of 
fibroblast precursor infiltration in response to injury (Sakai N. et al., 2006). Notably, human 
and murine fibrocytes look to be different. Murin fibrocytes express, CCR2 (Ekert JE et 
al., 2012), CCR3, CCR5(Abe R. et al., 2001), CCR7(Sakai et al., 2006) and 
CXCR4(Mehrad et al., 2007); Human fibrocytes express, CCR3, CCR5, and CXCR4 
(Mehrad et al., 2007), as well as b1-integrine subunit and Semaphorin 7a (Gan Y. et al., 
2011).  
Chemokine receptors drive fibrocytes recruitment to injury site in response to different 
chemochine (C-C or C-X-C motifs) ligands (CCLs and CXCL), as CCL2, 3, 5, CCL21 and 
CXCL12, relapse by cells of the injury site and other inflammatory cells (Moore et al., 
2005; Sakai et al., 2006; Ishida et al., 2007; Herzog et al., 2010).  
CXCR4-CXCL12 axis is the most describe in literature. The CXCR4 is an important 
receptor expressed by hematopoietic stem cells, which respond to CXCL12 signal, known 
as stromal cell-derived factor (SDF)-1 (Tamamis P. et al., 2013). It is a strongly chemotact 
signal for lymphocytes and macrophages, also plays an important role in embryogenesis 
and angiogenesis by recruiting endothelial progenitor cells (EPCs) from the bone marrow 
(Saini V et al., 2010). CXCL12 is involve into CXCR4
+ 
fibrocytes recruitment, as 
demonstrated by in vitro and in vivo studies of idiopathic pulmonary fibrosis (IPF) 
(Murdoch, 2000; Abe et al., 2001), which showed a direct correlation between the severity 
of the disease states and the activity of the chemokine axis, as between the plasma levels of 
CCL12 and circulating fibrocytes or infiltrated percentage, in IPF patients(Mehrad et al., 
2007; Andersson-Sjoland et al., 2008).  
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Under ureteral obstruction (UUO) mice experiments, an animal model of renal fibrosis, 
show a circulating fibrocytes recruitment dependent by CCR7 receptor and her ligand 
CCL21, as well as by CXCR4-CCL12 axis. These appear to work simultaneously but 
independently(Wada et al., 2011)  
Also, CCR2 receptor with her ligand monocyte chemoattractant protein (MCP)-1 (CCL2), 
and CCR5 with her natural ligand CCL5 ( also known as RANTES), or macrophage 
inflammatory proteins (MIP)-1α (namely as CCL3) and 1β ( as CCL4) are considered 
potential fibrocytes homing systems. These are involve into circulating monocyte and 
macrophage infiltration, mainly to inflammatory response and inflammatory diseases. Self-
determining studies conducted on both animal models and samples of human patients, 
shown important correlations between these chemotactic axis and fibrocytes recruitment in 
autoimmunity disease and other inflammatory process (Koch A.E. et al., 1992; Page G. et 
al., 2004; Yang M.H. et al., 2009). It may suggest a direct role of CCR5-CCL3/CCL4 and 
CCR2-CCL2 axis into circulating and tissue fibrocytes migration (Galligan et al., 2013). 
Furthermore, another research group has been demonstrated that CXCL16 is induced in the 
kidney during the pathogenesis of renal fibrosis; help the bone marrow-derived fibroblast 
precursors recruitment into the kidney, in a CXCL16-dependent manner. Fibroblast 
precursors express the CXCL16 receptor (CXCR6). Experimental investigation in vivo 
showed that targeted disruption of CXCL16 inhibits the recruitment of CD45-, collagen-I-, 
and CXCR6-positive fibroblast precursors in the kidney; and also reduces the severity of 
renal fibrosis and the expression of ECM protein. These to confirm that CXCL16 plays a 
pivotal role in the pathogenesis of renal fibrosis by recruiting bone marrow-derived 
fibroblast precursors into the kidney in response to obstructive injury.  
Fibrocytes express several chemokine receptors, signifying their potential recruitment to 
the sites of inflammation where the cognate chemokines are expressed (Galligan et al., 
2013). However, the signals mechanisms underlying the recruitment of circulating fibrocytes 
into the inflammatory site, as well in kidney injury, are incompletely understood. 
 
1.4. Function  
Fibrocytes display many functions that could influence the early phases of inflammatory 
process in response to tissue injury or invasion. Mostly early studies of fibrocyte biology 
centered on their role as a circulating source of contractile myofibroblasts. Precedent in 
vivo detection of fibrocytes transition to myofibroblast and collagen-producing phenotype 
in animal model of diseases (Mori L. et al., 2005; Kisseleva T et al., 2006), suggested a 
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circulating fibrocytes contribute to a subset of myofibroblast in wound and are integral 
mediators of wound-healing. Also, fibrocytes have been shown to promote angiogenesis, 
which is a requisite for the development and maintenance of new granulation tissue, 
allowing wound closure and restoration of tissue integrity. They participates in all aspects 
of neovascularization by secretion of vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), IL8, plateled derived growth factor (PDGF). They are 
also involved in the proteolysis of the basement membrane by constitutively secreting 
extracellular matrix degrading enzymes, as MMP-9, thus allowing for endothelial cell 
invasion (Blakaj A., et al., 2012).  
However, beside to minimal contribution of fibrocytes to α-SMA production as shown by 
lineage tracing studies in several models, fibrocytes respond to important mediator of the 
inflammatory response and possess other properties that regulate these phenomena, 
promoting tissue remodeling and repair (Peng H. et al., 2012).  
In experimental assays, in response to the IL-1β, a lymphocyte mitogen factor involved in 
a variety of cellular activities, including cell proliferation, differentiation, and apoptosis, as 
well as to TH1 cell cytokine release and/or viral infection, in human fibrocytes cultures 
downregulate collagen expression and increase production of IL-6, IL8, CCL3 and CCL4, 
which would promote inflammatory cell recruitment. In addition, there increase cell 
surface expression of leukocytes adhesion molecules, such as ICAM-1, which would 
increase leukocyte trafficking. However, at same condition response by increase IL10 
production reducing inflammation and beginning the ECM production and would be 
expected to recruit inflammatory cells and promote tissue repair and remodeling (Chesney 
J., et al., 1998). If cultured in serum-supplemented medium, as might occur in acute injury, 
fibrocytes have a macrophage-like inflammatory gene program characterized by the 
expression of gene encoding chemokine receptor, cytokines and molecules involved in 
antigen presentation and lipid metabolism (Curnow S.J. et al., 2010).  
Fibrocytes express of MHC class I and II molecules and CD80/CD86 co-stimulatory 
proteins, that allow an antigen-presenting function to CD8
+
cells inflammatory cells 
(Balmelli C. et a., 2005), such as possess antigen-presenting property and under certain 
conditions may induce a mixed TH1/TH2 response in CD4
+ 
cells (Medina A. et al., 2011), 
suggesting an important role in early events mediating inflammation. Similarly, when these 
respond to the presence of apoptotic cells by increasing collagen production and repair 
(Peng X., et al., 2011).  
This information indicate that circulating fibrocytes can respond to injury and 
inflammatory stimuli by take-up the functional characteristics of both classical and 
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alternatively activated macrophage , as well as of fibroblast and myofibroblast. Whether 
the inflammatory or reparative fibrocyte phenotype dominates probably depends on 
dynamic process governed by local factor (see fig. 1). 
 
 
 
Figure n°1 : Potential roles of f ibrocytes in chronic inflammatory disease. (Reilkoff LA., et 
al.,  2011)  
 
1.5. Fibrocytes in chronic inflammation and fibrosis 
Chronic inflammatory reaction induced by a variety of stimuli, including persistent 
infection, autoimmune reactions, allergic responses, chemical insults, radiation and tissue 
injury result into a common end-stage know as fibrosis. Although initially repair process 
induces a generative phase, the persist of injury cause ongoing immune activation and 
impeded repair.  
Usually, adult wound healing, often result in a dysregulated pathogenic condition, which 
show a chronic inflammation response characterized by replacement of normal structure 
whit inflammatory cells and tissue remodeling. Excess deposition of extracellular matrix 
components including collagen derive by both infiltrated inflammatory cells and resident 
fibroblast, as well as by matrix-producing cells, epithelial/endothelial-mesenchymal 
transition cells (EMT/EndMT cells) and bone-marrow derived cells switched to a 
myofibroblast phenotype. It lead to hypertrophyic tissue, hardering, and/or scarring, and 
fibrosis. Given the combination of ongoing inflammation and fibroblast-drive end-organ 
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remodeling seen in chronic inflammatory disease, circulating fibrocytes emerged as an 
important players in heterogeneous chronic inflammation conditions. However, most 
recent studies of fibrocytes have focused on describing their associations with various 
pathologic inflammatory conditions, but their effect and contributions to inflammatory 
pathologies remain unknown. The association between fibrocytes and heterogeneous 
chronic inflammatory conditions indicates that they have a role extending far beyond ECM 
production regulated by the local milieu (see fig. 1, above), (Peng H. et al., 2012). 
A paradigm, based on fibrocyte futures and inflammatory process known, suggest that 
circulating fibrocytes recruited early during an inflammatory response have a pro-
inflammatory phenotype that is induced by acute injury or autoantigen exposure, or 
following stimulation by local factors (i.e. IL-1β), serum factor and innate immune signals. 
During this state, fibrocytes amplify the immune response by both pro-inflammatory factor 
release and other cells recruitment (as limphocytes, macrophages and fibrocytes 
themselves). Later, as inflammation regresses and repair and remodeling begin, a 
programme of matrix production and myofibroblast transformation by fibrocytes ensues. 
Increased numbers of local and/or circulating fibrocytes have been identified in diseases 
characterized by chronic TH1 and TH2 cell-mediated inflammatory responses 
(autoimmunity), TH1 cell-dominant responses (cardiovascular disease) or TH2 cell-dominant 
responses (asthma), (Reilkoff R.A. et al., 2011), as well as into different form of fibrosis, 
as pathological end-stage, including: lung, skin, liver and kidney, as well as into airway 
remodeling, in asthma and aging process (Peng H. et al., 2012; Mackinnon A., et al., 
2013). 
1.5.1. In Aging  
Dysregulated inflammatory process are seen in otherwise aged individuals healthy. While 
the factors engage remain unclear, some studies propose a fibrocytes involvement.  
Models of  senescence-accelerated mice shows increased circulating and intrapulmonary 
fibrocytes (Xu J. et al., 2009). Col-1-luciferase mouse model proves same higher level of 
fibrocytes into the blood of aged mice, compared to young mice, also these imaging studies 
suggesting that CCR2 and CCR3 chemokine receptors could be related to fibrocytes 
trafficking (Scholten D. et al., 2011). Interestingly, increased fibrocyte precursors were 
seen in the circulation of aged healthy humans, compared to younger subjects (Mathai SK. 
et al., 2010). However, will be needed more studies  to determine whether fibrocytes play a 
role in age-related tissue dysfunction.  
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1.5.2. In autoimmunity disorders 
Emerging evidence indicates that fibrocytes have an involvement in the autoimmune 
effectors pathway and participate to the fibroblast-like cells in human form and mouse 
models of scleroderma, autoimmune thyroiditis and rheumatoid arthritis. A role for 
fibrocytes in autoimmune pathogenesis is suggested by studies of patients with diffuse 
scleroderma, a TGFβ1-driven multisystem autoimmune disorder characterized by 
progressive cutaneous and visceral fibrosis. Patients shown uncontrolled collagen 
production by activated myofibroblasts, which also secrete the chemotactic and 
lymphocyte-activating protein ICAM1 (Needleman B.W. et al., 1990), as well as the pro-
inflammatory cytokines (as IL6, IL8, TGFb, PDGF), (Kadono T. et al., 1998). A flow-
cytometric analysis of circulating or culture monocytes shows an increased number of 
fibrocytes, in scleroderma-related interstitial lung disease patients whit scleroderma related 
to lung fibrosis (Tourkina E. et al., 2011) as amniotic antisynthetase syndrome (Peng X. et 
al., 2011). Further support become from the recent finding of increased fibrocyte numbers 
in individuals with Graves’ disease, an autoimmune thyroid disorder characterized by 
persistent inflammation, lipogenesis and fibrosis in the retro-orbital space (thyroid-
associated ophthalmopathy), where the peripheral blood and retro-orbital fad pat shown a 
high frequency of fibrocytes and displaying high expression of several pro-inflammator 
mediators (Douglas RS. et al., 2011). Pro-inflammatory mediator role of fibrocytes in the 
pathogenesis of this disorder was suggested by a study in which CD34+, CXCR4+, 
CD11b+ and pro-collagen I+ cells showed high levels of the insulin-like growth factor 1 
(IGF1) receptor, that lead to high-level secretion of pro-inflammatory cytokines such as 
TNF and IL-6 (Muller-Ladner, U. et al., 2007), and the expression of thyroid-stimulating 
hormone (TSH) receptor, a potential target of autoimmunity in this disease(Bahn, R.S., 
2010). Fibrocytes are also associated in rheumatoid arthritis seen in the synovial 
inflammatory fluid of these patients (Muller-Ladner, U. et al., 2007). Although they are not 
found with increased frequency, these possess both the pro-inflammatory and tissue 
remodeling properties generally attributed respectively to synovial macrophage and 
synovial fibroblast. However, a role for fibrocytes in the inflammatory pathogenesis of 
chronic synovitis is supported by studies documenting the appearance of activated 
fibrocytes before the development of arthropathy in the collagen-induced arthritis murine 
model of rheumatoid arthritis (Galligan CL. et al., 2010) 
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1.5.3. In cardiovascular diseases 
Cardiovascular disease follow a paradigm of macrophage-driven inflammatory changes in 
blood vessels that lead to late the formation of an fibrous cap, known as fibroatheroma, 
characterized by an accumulation of lipid and inflammatory cells inside, and a connective 
tissue for an increased of myofibroblasts and excessive deposition of collagen and other 
ECM molecules, which are stimulate by different pro-fibrotic factors produced locally by a 
wide variety of cells (Reilkoff R.A. et al., 2011) 
The remodeling process in the arterial vessel wall results in atherosclerotic plaque (Stary 
HC. Et al., 1995) and stenosis of the vessel (Andreeva ER., et al., 1997). Atherosclerosis in 
coronary arteries could happen to myocardial infarction and fibrosis of cardiac tissue. 
Clinical significance of this lesion is largely dependent on its composition, which is 
determined by the balance between inflammation and fibrosis and affects the stability of 
the plaque. Fibrocytes are implicated in the development of both vascular plaques and 
myocardial fibrosis, although their precise contributions to disease pathology may vary 
(Reilkoff R.A. et al., 2011).  
Fibrocytes co-expressing pro-collagen I and CD34 have been identified in the fibrous cap 
of human atherosclerotic lesions (Medbury, H. et al., 2008). Also, subendothelial 
myofibroblasts expressing the monocyte marker CD68 or CD34 have been found in lipid-
rich areas of the atherosclerotic intima in human aorta (Medbury H et al., 2007), and in the 
fibrous cap of human carotid arteries, suggesting a fibrocyte origin for these cells 
(Andreeva ER et al., 1997).The accumulation of fibrocytes in the fibrous cap of the 
atherosclerotic lesion may have a beneficial effect in stabilizing the plaque that outweighs 
the detrimental increase the expantion of the fatty core, so in plaque volume (Medbury H et 
al., 2007). Also, several models of animal disease, as apolipoprotein E (Apoe)-null mice 
(model of human atherosclerosis) suggesting that fibrocytes mediate TGFβ1-induced 
events in this model (Buday, A. et al.2010), and that fibrocytes don’t adopt the fully 
differentiated phenotype of either macrophages and fibroblast in atherosclerotic cup but 
remain relatively undifferentiated, as shown by their persistent expression of CD45 and 
coll Iα (Iwata, H. et al.2010). This might reflect the fact that fibrocytes are unable to form a 
discrete effector population given the ongoing injury and impeded repair seen in this 
disease.  
However, in a setting of profound initial injury or persistent damages, or in presence of 
pro-fibrotic inflammatory stimuli, fibrocytes could contribute to develop of cardiac fibrosis 
and remodeling that ensue. Although fibrocytes have been found in myxomatous human 
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heart valves, characterized by an abnormal connective tissue composition (Barth P.J. et al., 
2005), they have yet to be identified in the normal human myocardium. 
Indeed, human ischaemic cardiomyopathy murine models indicates that fibrocytes might 
contribute to the pathogenesis through they recruited to chronically injured myocardium, 
where they constitute up to 3% of the total number of heart cells and involving to ECM 
production, although it is possible that other activities that are more typically associated 
with both macrophages and fibroblasts such as cytokine production, immune cell activation 
and angiogenesis. Thus, fibrocytes might have a protective or reparative effect in the 
setting of uncontrolled or persistent in vivo TH1 cell cytokine exposure, whereas in 
response to persistent TH2 cell cytokine exposure (as occurs in the remodeled heart) this 
phenotype becomes profibrotic (Reilkoff R.A. et al., 2011). 
1.5.4. In Asthma and Idiopatic Pulmonary Fibrosis 
Fibrocytes are associated with many form of chronic inflammatory lung disease. 
Elevations on circulating fibrocytes and intrapulmonary fibrocytes are seen in patient with 
several forms of airways remodeling including chronic persistent asthma and allergic 
asthma. Compelling evidence was provided by a study in which bronchoscopic lung 
biopsies obtained from patients with asthma after allergen inhalation showed localization 
of fibrocytes (coll I
+
, CD34
+
), in the airway submucosa; also, in the same study, the use of 
mouse ovalbumin models in murine studies of asthma have found that after allergen 
inhalation fibrocytes localize to the airway mucosa, were they acquire a myofibroblast 
phenotype in presence of inflammatory cytokines (Schmidt M. et al., 2003). The high 
numbers of circulating fibrocytes in patients with asthma has been registered only in those 
individuals with chronic airway obstruction, respect to mild asthma and health subjects, 
were they correlated whit basement membrane thickness, by a TGF-β1-dependent increase 
in proliferation and α-SMA production, and whit the disease severity (Nihlberg K., et al. 
2006). However, fibrocytes were also found (in few number) in the lungs of patients with 
mild asthma, indicating that they might have an important role in early inflammatory 
progression (Nihlberg K., et al. 2006). In a murine models of obliterative bronchiolitis 
using heterotopic tracheal transplantation, circulating fibrocytes engrafted the tracheal 
allograft and differentiated into fibroblast (Harris D.A. et al., 2012)  
In fibrotic lung disease, the number of accumulating fibrocytes may be as much as 25% 
(Strieter R.M. et al., 2009), and may significantly contribute to pulmonary fibrosis. 
Experimental studies on murine model of this pathology has been shown fibrocytes traffic 
to lung following bleomycin challenge, both human fibrocytes in SCID mice and mouse 
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fibrocytes in immune-competent mice (Pilling R.J. et al., 2004; Hashimoto N. et al., 2004). 
Elevated level of circulating fibrocytes and intrapulmonary fibrocytes have been reported 
in patient whit idiopathic pulmonary fibrosis (IPF), where their presence correlated whit 
poor prognosis (Moeller A. et al., 2009), and had increased during acute exacerbations of 
the disease. Similarly, high number of fibrocytes are seen in the bronchoalveolar lavage 
fluid of patients with Acute Respiratory Distress Syndrome (ARDS) compared to 
mechanically ventilated patients without ARDS, who went on to show increased mortality 
(Quesnel C., et al., 2012) 
1.5.5. In liver fibrosis  
Several investigation on mouse model of liver fibrosis had been shown an involvement of 
fibrocytes in the liver injury, but they role is not to be clear, and under debate. Fibrocytes 
were identified in the bile-duct ligation model of murine liver fibrosis, although these 
bone-marrow derived cells reveled in the tissue comprised a small fraction of hepatic 
stellate cells, which mediate collagen deposition in this model (Kisseleva T., 2006). Also, 
other result on experimental models indicate the fibrocyte participation to this pathology. 
A murine imaging study using in vivo imaging of collagen-I driven luciferase reporter 
gene (coll I-Luc) found that fibrocytes traffic to the disease to the engagement of the 
chemokine receptor CCR1 and CCR2 and differentiate into myofibroblasts (Scholten D et 
al., 2011); Similar populations has been identified in the spleens of mice treated whit TGF-
β1, lipopolysaccharide, viral infection or carbon tetrachloride (to induce the liver injury), 
also these cells expressed MHC-II and stimulated naïve T cells in addiction to their modest 
production of ECM and α-SMA (Kisseleva T. et al., 2012), thinking of a fibrocytes 
participation in the early phases of fibrosis via initiation and perpetuation of host immune 
responses. 
While similar phenomena has yet to be identified in human liver fibrosis, where there has 
been a suggestion that a modest portion of the myofibroblasts-like cells (no more 12%) in 
the liver may have bone-marrow origin. Liver biopsies for recurrent fibrosis, in male 
patients that had received female liver transplantation, showed a proportion of the 
myofibroblasts were marked whit the chromosomal markers of the recipient (Y 
chromosome positive), suggesting a potential circulating origin. Furthermore, histological 
analysis of liver biopsies showing a portion of myofibroblasts contain the Y chromosome 
in female patients, who have received male bone-marrow transplantation, and then to go to 
develop liver injury, suggested potential bone-marrow origin (Forbes S.J. et al., 2004). 
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However, characterization and participation in chronic liver inflammation remains to be 
understood.  
1.5.6. In skin and systemic fibrosis 
Although there are numerous reports in mice suggesting that bone-marrow derived cells 
may be engraft skin and produce cells of a fibroblast or myofibroblast futures (Direkze 
N.C. et al., 2003), the few subsequent experiments of fibrogenesis and wound healing 
response in mouse model showed a trifling involvement of bone marrow origin whit 
CD45
+
/Coll I
+
 cells (possibly fibrocytes) (Higashiyama R. et al., 2011; Barisic-Dujmovic 
T. et al., 2010). However there is mounting evidence that circulating fibrocytes may 
contribute to fibrosis in skin following irradiation (Delanian S et al., 1998) and in the skin 
of patients affect by nephrogenic system fibrosis disease.  
Nephrogenic system fibrosis (NSF) is a disease that occurs almost exclusively in patients 
whit renal dysfunction, in particular in those undergoing hemodialysis for end-stage renal 
disease. The clinical course is characterized by symmetric and hardening of the skin and 
involve multiple organ as heart, lung, skeletal muscle and diaphragm, has been reported in 
many patients, and it can lead to death. The pathogenesis is not clear but it has been 
associated whit the use of gadolinium-containing contrast agents for magnetic resonance 
(Bellini et al. 2007), in particular in  the tissue of the patients that have metabolic acidosis 
or other condition that favor the liberation and  deposition of the toxic gadolinium ions (as 
renal failure) (Grobner T., 2006). Several studies, in human patients and animal models of 
the disease, describe the presence of vascular calcium deposit, also interstitial gadolinium 
and calcium phosphate storages. In the tissue involved, has been shown the presence of 
fibrotic lesion whit a fibro-proliferative process and a dense infiltrate composed by 
monocytes and abundant spindle-shaped cells, immersed in a profuse ECM. The 
expression of CD45 and CD34 myofibroblast-like cells of the lesion has been detect in the 
areas of active fibrogenesis, well in the early stage of the fibrotic process (Bellini et al. 
2007). In particular, Cowper et colleagues describe double staining cells for CD45 and pro-
Coll I, demonstrating that these cells are really fibrocytes (Cowper et al., 2003). Also, It 
has been proposed that same cells may been involved in the pathogenesis of systemic 
sclerosis (Postlethwaite A.E. et al., 2004). A connective tissue disease characterized by 
autoantibody production, microvascular stenosis and excessive collagen deposition in the 
skin lesions and other organ involved (Bellini et al. 2007), as demonstrated by studies 
described above. 
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1.5.7. Fibrocytes in other chronic inflammation and cancer  
Reactive fibrosis are a prominent features of chronic pancreatitis (CP), chronic cystitis and 
gut chronic tissue inflammation, as colitis. Such diseases shown a chronic inflamed process 
that engage an active status of local and circulating cells engraft, leading to the release of 
ECM elements and tissue remodeling. 
Stromal cells expressing CD34 have been found in patients with chronic cystitis (Nimphius 
W, et al., 2007), as in experimental models and human tissue analysis of gut inflammation 
and colitis in which bone-marrow derived cells has been reveled confined to the non-
epithelial compartment (Lee C.Y. et al., 2011). 
With reference to human tissue, unlike to health pancreatic stroma, the accumulation of 
fibrocytes-like cells appeared to be associated with a parallel increase in the CD34 
fibrocytes and α-SMA+ myofibroblast populations, in chronic pancreatitis and ductal 
adenocarcinoma (Barth PJ, Ebrahimsade S et al., 2002). Also, two in vivo studies, a model 
of CP by cerulean injections (Watanabe T. et al., 2009), and a mouse dietary model of 
pancreatitis (Akita S. et al., 2012) reveled a 20% of α-SMA+  activated pancreatic stellate 
cells whit bone-marrow origin and pro-inflammatory factors (PDGF and TGF-β1) 
production by these. However, the CD34 positivity by stromal cells and their real 
contribution to the population of lesional myofibroblast in these pathologic conditions 
remains to be elucidated. 
Immature monocytes with bone-marrow origin are actively recruited into solid tumor from 
circulation and represent an important compartment of leucocyte infiltrate in malignant 
lesion. The presence of fibrocytes-like stromal cells CD34
+
 has been detected in varius 
human benign and invasive tumors (Bellini et al., 2007). Histological analysis of human 
tissue sections for CD34 and α-SMA markers, revealed that CD34+/α-SMA-  fibroblast are 
usually found in the stromal capsule of benign tumor, whereas around carcinoma CD34
-/α-
SMA
+
 myofibroblast are more frequent (Barth PJ, Ramaswamy A et al., 2002; 
Ramaswamy A et al., 2003; Chauan H. et al., 2003; Barth PJ, Schenck zu S.T. et al., 2004). 
Furthermore,  The presences of excessive levels of TGF-β1 and ET-1 in the tumor micro-
environment could trigger the CD34
+ 
fibrocytes into active myofibroblst (CD34
-/α-SMA+). 
The pro-angiogenic activity of fibrocytes (Hartlapp I, et al., 2001), also suggests that these 
may potentially contribute to the metastatic progression of invasive carcinoma. As reveled 
by in vivo experimental model, CD45
+
/ CD34
-/α-SMA+ cells with fibrocytes phenotype, 
that undergoing into mature myofibroblast, have been identified in cancer-induced stroma 
in advance stage of an implanted large-cell neuroendocrine carcinoma in bone marrow 
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chimera mice (Ishii G., 2005). In conclusion, fibrocytes may be an inducer of tumor escape 
from host immune surveillance through they both actigen-presenting activity and the 
ability to regulate cytotoxic T lymphocytes (Bellini et al., 2007).  
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2. Chronic Kidney Disease and Renal Fibrosis 
2.1. CKD epidemiology, etiology and classification 
Healthy kidneys play several essential regulatory roles in the human body. They perform 
homeostatic functions such as the regulation of electrolytes, maintenance of acid-base 
balance, regulation of blood pressure (via maintaining salt and water balance). They filter 
the blood removing wastes (i.e. urea, creatinine, ammonium) and foreign materials (i.e. 
drugs). The kidneys  also have an endocrine function playing a part in the production of 
vitamin D and erythropoietin and as part of the renin/angiotensin/aldosterone axis. 
Kidney disease is defined as a heterogeneous group of disorder affecting kidney structure 
and function which can occur abruptly and either be resolved or become chronic and 
evolve into end stage renal disease (ESRD). (Levey AS et al., 2013). Is necessary to 
distinguish two main forms of renal failure: 1) acute kidney injury (AKI), an abrupt loss of 
kidney function that develops within 48 hours, which is often reversible within three 
months with adequate treatment; 2) chronic kidney disease (CKD), which can involve in 
the end-stage renal disease (ESRD). There is a complicate relationship between AKI and 
CKD; AKI can lead to CKD, and CKD increases the risk of AKI (Bedford M. et al, 2012). 
Chronic Kidney disease (CKD) is a general term for heterogeneous disorders affecting 
kidney structure and function with variable clinical presentation, which is present for >3 
months. The progressive nephron and GFR loss associated with progressive CKD leads to 
(1) abnormalities in water, electrolyte, and pH balance, (2) accumulation of waste products 
normally excreted by the kidney, and (3) abnormalities in the production and metabolism 
of certain hormones (ie, erythropoietin, active vitamin D). 
Chronic kidney disease is a common and growing problem worldwide.   The adjusted rates 
for incident and prevalent ESRD in the United States (US) in 2008 were 351 and 1,699 
cases per million population (pmp), respectively (USRDS 2010). The estimated incidence 
and prevalence of renal replacement therapy in 25 countries of the European Union was 
137 pmp, and 786 pmp, respectively (Lameire N et al., 2005). The last decade has seen a 
dramatic 5-6% increase per annum in the number of patients with newly diagnosed ESRD 
(Samuel CS and Hewintson TD. 2009).  
The etiology is really heterogeneous and most risk-factor are known. The two main causes 
of kidney disease are systemic hypertension, that damage the small blood vessels in the 
kidneys, and diabetes where hyperglycemia is associated with an increase in mesangial cell 
proliferation and hypertrophy, as well as increased matrix production and basement 
membrane thickening. Hypertension and diabetes are responsible for up to two-thirds of 
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the cases of CKD. Glomerulonephritis, inherited diseases (i.e. polycystic kidney disease or 
Alport’s syndrome), autoimmune diseases (i.e. systemic lupus erythematosus), 
amyloidosis, infections (e.g. hepatitis C, tuberculosis, HIV and parasitic infection), 
nephrotoxic agents (e.g. analgesics and radiological contrast media),  obstructions caused 
by tumors, kidney stones or an enlarged prostate gland in men and repeated urinary 
infections are other most frequent causes of CKD. These diseases can attack and damage 
the tiny glomerular vessels with different mechanisms. Also accidents, injuries or 
complications from surgeries in which the kidneys are deprived of normal blood flow, such 
as trauma and a direct and forceful blow to the kidneys, can lead to kidney injury.  
Kidney disease differs from most other organ systems disorders because it is often “silent”. 
Few symptoms, often non-specific, can appear only in the late stages of the disease (Levey 
AS et al., 2011). As the GFR declines, a number of compensatory mechanisms are 
activated, of which the most important is glomerular hyperfiltration in the remaining 
functioning nephrons. Due to this compensatory mechanism, a patient may be totally 
asymptomatic despite having lost 70% of kidney function. However, glomerular 
hyperfiltration is associated with the development of glomerulosclerosis in the remaining 
functioning nephrons, which contributes to further nephron loss. Beyond a certain level of 
damage, the compensatory adaptation is no longer holding the hand with the loss of 
nephrons, with consequent reduction in glomerular filtration rate and reduced elimination 
of organic nitrogenous wastes (e.g. creatinine, urea). (Brenner BM, 2002).  
When the GFR falls to approximately 10–15 mL/minute, nonspecific symptoms such as 
general malaise, weakness, insomnia, inability to concentrate, nausea and vomiting begin 
to appear. Other symptoms and signs that reflect generalized organ dysfunction develop as 
part of the uremic syndrome, such as volume overload leading to edema and systemic 
hypertension.  
In addition to an elevated blood urea nitrogen (BUN) and serum creatinine, which are a 
reflection of a decreased GFR, patients with progressive CKD develop other laboratory 
abnormalities including hyponatremia (due to excessive water intake), hyperkalemia, 
hyperphosphatemia, hypocalcemia, hypermagnesemia, and hyperuricemia. Metabolic 
acidosis, usually with an elevated anion gap, is also common. Anemia and renal 
osteodystrophy can complicate later stages of the disease, while cardiovascular 
manifestations are the most common cause of morbidity and mortality among patients with 
progressive CKD. 
According to KDOQI and KDIGO guidelines CKD is defined by the presence of kidney 
damage or decreased kidney function for three or more months, irrespective of the cause 
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(Kidney Int Suppl. 2013;3:19). Identifying patients with CKD can therefore be done 
without identification of the underlying cause but identifying the cause of kidney disease 
enables specific therapy directed at preventing further injury. The persistence of the 
damage or decreased function for at least three months is necessary to distinguish CKD 
from acute kidney disease. Kidney damage refers to pathologic abnormalities, whether 
established via renal biopsy or imaging studies, or inferred from markers such as urinary 
sediment abnormalities or increased rates of urinary albumin excretion (table n° 1). 
Decreased kidney function refers to a decreased glomerular filtration rate (GFR), which is 
usually estimated (eGFR) using serum creatinine and one of several available equations. 
 
 
 Functional Criteria Structural Criteria 
AKI 
Increase in SCr  by 50% within 7 days, or increased in SCr 
by 0.3 mg/dL within 2 days, or oliguria 
No Criteria 
CKD GFR< 60 mL/min for >3 months Kidney damage for > 3ms 
AKD 
AKI or GCF<60 mL/min/1.73 m
2
 for <3 months or 
decreased in GFR by >35% or increase in SCr by >50% for 
<3 months 
Kidney damage for < 3 ms 
NKD GFR > 60 mL/min/1.73 m2, stable SCr No damage 
 
Table n°1: Criteria for normal or not damage,  A KI and CKD proposed by KDIGO guidelines.  
Abbreviations: AKD, acute kidney disease, AKI acute kidney injury, CKD chronic kidney 
disease, GFR glomerular filtration rate; NKD, no known kidney disordes; SCr, cerum 
creatinine. (Levey AS., et al.,  2013)  
 
 
In current CKD nomenclature used by KDIGO, CKD is classified based on cause, GFR 
category, and albuminuria category (using urine albumin-to-creatinine ratio or urine 
protein-to-creatinine ratio) and is outlined in 5 stages (table n°2)  
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Table n 2: Prognosis of CKD by GFR and albumin Categories  (KDIGO Clinical Practice 
Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney 
International Supplements (2013) 3, 19 -62).  
 
In stage 1 CKD renal function is normal but there is evidence of urine findings or structural 
abnormalities. Stages 2 and 3 need increasing levels of supportive care to slow and treat 
renal dysfunction. Patients in stages 4 and 5 usually require preparation towards active 
treatment in order to survive. Stage 5 CKD is considered a severe illness and requires some 
form of renal replacement therapy (dialysis) or kidney transplant whenever feasible. 
Epidemiology and clinical evidence show link between several factors and the initiation 
and the progression of CKD. Hypertension, diabetes, hyperlipidaemia, obesity and 
smoking are risk factors or markers in the general population for the development, but at 
the same time contributes to the progression of injury. Genetic and familiar predisposition, 
age, geographical origins and sex are considered “susceptibility factors” (El Nahas AM, 
Bello AK, 2005). 
 
2.2. CKD and kidney damage progression  
CKD could be develop by primitive glomerular injury, as in segmental and focal 
glomerulosclerosis or nephropathy IgA deposits, or tubulointerstitial injury as in polycystic 
disease or in nephritis induced by drugs and reflux nephropathy. Moreover it could be a 
consequence of a pathology with different origin as hypertension, systemic dysfunction by 
vascular origin with involvement of the great vessels, as in bilateral renal artery stenosis, or 
small-vessel vasculitis.  
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Also metabolic diseases such as diabetes mellitus (i.e. diabetic nephropathy), lupus 
nephritis, renal lithiasis, infectious diseases can attack the kidneys, causing kidney failure. 
Patients who have recovered from an episode of acute kidney failure, whether due to acute 
tubular necrosis or other parenchymal diseases, may also be at risk of developing chronic 
kidney disease (Schrier R.W. 2010). 
The progression of CKD depends by several mechanisms with common final pathway: 
glomerular hypertension, renal proteinuria, hyperlipidaemia, tubular cell biology, 
interstitial immunology fibroblast formation and fibrosis. Regardless initial renal damage, 
if it persist can lead to glomerulosclerosis and hyperfiltration followed by tubular 
interstitial injury, or conversely, with a final common pathway involving into interstitial 
nephritis and fibrosis (Risdon RA et al, 1968; Brenner BM, 2002). 
Chronic inflammatory response with progressive loss of remaining tissue, until beyond a 
certain threshold of damage, it triggers a mechanism of self perpetuation and aggravation 
of the same, as postulated by the “self-perpetuation hypothesis”.( Brown et al., 1997; 
Brenner BM, 2002).  
Persisted glomerular injury produce elevation in glomerular capillary hydraulic pressure 
(Pgc) (Chen JK et al. 2005). In response, the compensatory action induced by cells factors 
release (i.e. aldosteron, AngII and ROS) lead to hypertension in capillary tufts as well as 
glomerular hypertrophy. Also, glomerular podocytes are inability to cover the increased 
surface, so these undergo to detachment. Segmental denudation of the capillary wall whit 
capillary tuft adhesions to Bowman’s capsule, followed by segmental collapse, increase the 
single nephron glomerular filtration rate and protein leak into tubular fluid. The remaining 
nephrons lose their ability to autoregulate, systemic hypertension is transmitted to the other 
glomerulus, worsening the pathologic condition. 
Hemodynamic alteration induce glomerular proteinuria, which involves into the injury of 
interstitum and tubular atrophy. This follow by an inflammatory response with downstream 
cytokine and chemokine with other concurrently pro-inflammatory and hemodynamic 
factors that induces an accumulation of interstitial mononuclear cells (Harris R.C. et al., 
2006). The immunologic mechanisms for spreading include loss of tolerance to 
parenchymal self, immune deposits that share cross-reactive epitopes in both 
compartments and glomerular injury that reveals a new interstitial epitope (Kuncio G.S., et 
al, 1992). 
The initial appearance of interstitial neutrophils is quickly replaced by gathering 
macrophages and T lymphocytes, mediated by increased cytokines production that form a 
nephritogenic immune response, producing interstitial nephritis, tubular damage, apoptosis 
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and sustained inflammatory response (Taal MV et al., 2000). Simultaneously, profibrotic 
growth factors and inflammatory cytokines cues induce different cellular events include 
mesangial cells and renal fibroblast activation, such as podocytes, endothelial and tubular 
epithelia cells transition to fibroblastic/mesenchymal phenotype. New interstitial 
fibroblasts increase the number of tissue fibroblasts kindles fibrogenesis, that lay down a 
collagenous matrix that disrupts adjacent vasa recta and tubular nephrons, eventually 
leaving (El Nahas AM, Bello AK, 2005). 
For reasons yet to be fully understood, the regeneration of kidney tissue damage occurs in 
the fetus only, whereas the morphological and functional recovery of the parenchymal 
tissue in the adult is partial and tied to the attempt to compensate for the damage suffered 
through the healthy nephrons (Hewitson, 2009). Kidney structure is replaced with 
connective tissue by an excess accumulation of extracellular matrix through a chronic and 
auto-sustained process involving in interstitial nephritis and renal fibrosis (or scarring). 
Regardless where injury begins,  the kidney will go to gradually self-destruct until to stage 
5 of CKD, also known as end-stage of renal disease (ESRD) (Liu Y. 2006). ESRD occurs 
when renal parenchyma tissue is reduced to less than 5%, as observable during an 
histological analysis (Bohle A. et al., 1987). That lead to a progressive and irreversible loss 
of kidney function until the need for replacement therapy, such us dialysis or kidney 
transplant (Eddy AA, 2005). 
 
2.3.  Renal Fibrosis 
Conceivably, each and every one of these pathological features could contribute to the 
relentless progression of the destruction of renal parenchyma and loss of kidney functions. 
The wide range of pathophysiologically distinct processes that lead to chronic kidney 
disease (CKD) converge on a common pathway that results in glomerulosclerosis, 
progressive interstitial fibrosis, peritubular capillary rarefaction and destruction of 
functioning nephrons for a tubular atrophy (Eddy A.A., 2005). Tissue injury provokes 
inflammation as the host defense mechanism in response. Depending on the etiology of 
renal failure, glomerular or interstitial infiltrated inflammatory cells become activated, and 
produce injurious molecules such as reactive oxygen species (ROS), as well as fibrogenic 
and inflammatory cytokines and growth factors. 
Renal fibrosis is characterized by the development of excessive extracellular matrix (ECM) 
plaques in the tissue interstitium that compromise kidney function and result in eventual 
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tubulointerstitial injury, the ultimate outcome of chronic renal injury (Risdon R.A.et al. 
1968).  
Normal wound healing, inflammation is an early beneficial response to injury, and it is 
spontaneously resolved once the repair and recovery is completed. The connection between 
inflammation and fibrosis is that they are mediated in a paracrine fashion, whereby 
inflammatory cells secrete profibrotic cytokines that act on resident fibroblast and tubular 
cells. However, non resolving inflammation after chronic injury is relentless drive of 
fibrogenesis because it creates a vicious cycle of inflammation, tissue damages and 
fibrosis. Consist in a failure of the wound healing response to resolve in situation of 
ongoing (chronic) insult. Renal fibrogenesis is considered to be a failed wound-healing 
response to tissue injury, or injurious stimuli, where the balance between the pro- and anti- 
inflammatory factors, particularly between the self-limited repair and exuberant 
accumulation of extracellular matrix has been tipped in favor of the latter. What factor 
determines whether inflammation is a physiologic response or a driving force for tissue 
destruction remains elusive. Key events of kidney fibrosis, usually identified as 
tubularinterstitial fibrosis, is not restricted to the interstitium region. Also, take place in the 
glomeruli after injury, which include glomerular infiltration of inflammatory cells and 
implication of mesangial cells and podocytes. In many aspect, major fibrogenic mechanism 
are common and shared by different tissue compartment in the kidney (Liu Y. 2011).  
On the basis of the sequence of destructive events, the pathogenesis of renal fibrosis is 
“artificially” divided into four overlapping phases: priming, activation, execution and 
progression (Liu Y., 2006). However, despite this arbitrary division, is a dynamic process 
in which many of these events occur concomitantly.  
After the initial injury, the affected kidney tissue undergo a series of events in an attempt 
to repair and recover from the damage with a localized inflammatory response, by creating 
an apoptotic and pro-inflammatory niche. These processes, identified as priming phase, 
include kidney resident cell persistent stimulation by almost of renal injured described 
above, which leads to the production and secretion of proinflammatory factors such us 
cytokines and vasoactive molecules, as endoelin (ET)-1 and angiotensin (Ang)-II. Nuclear 
factor (Nf) kB is one of the key drive of this inflammatory process, it is triggered by 
connective-tissue growth factor (CTGF), hypoxia, Ang-II, aldosteron, such as for protein 
from tubular fluid in the both proteinuria and tubular stretch conditions. Its factor induce 
the production of pro-inflammatory and pro activator molecules such as plasminogen 
activator inhibitor (PA-1), interleukin (IL)-1, IL-6, chemokin (C-C motif) ligand 2 (CCL2), 
CCL5 and tumor necrosis factor (TNF)-α by the injured tubular epithelial cells (Chuang 
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P.Y. et al. 2013). A chemotactic gradients provide a directional signal for lymphocyte T 
cells, dendritic cells, monocytes/macrophages, mast cells and fibrocytes to the injury sites. 
The increase of expression of monocyte chemoattractant protein (MCP)-1, of the 
complement proteins C3 and C5, that attract monocytes and macrophages in interstitial 
level, and cell adhesion molecules such as intercellular adhesion molecules (ICAM)-1, the 
vascular cell adhesion molecules (VCAM)-1 and osteopontin-1, helping cell migration into 
the interstitium (Eddy A.A., 2000) 
 Recruitment and activation of T lymphocyte could be considered an important early event 
that mediates the onset of renal fibrogenesis, specially CD4+T cells (Tapmeier T.T. et al., 
2010). It followed by the macrophage recruitment to the injury site, which differentiated 
into two broad but distinct subset categorized as either classical activated (M1) or 
alternatively activated (M2). In general, M1macrophage display a typical proinflammatory 
phenotype, produce a variety of chemokines, as well as ROS, and therefore have 
pathogenic function (Liu Y., 2011); M2 have been shown to mitigate renal fibrosis (Wang 
Y. et al. 2007), with mast cells role (Miyazawa S. et al. 2004). In addition to the soluble 
mediator, findings also indicate that monocytes and tubular cells might be require to induce 
tubular EMT, important ongoing phenomenon of fibrosis, by monocyte via an NF-kB 
dependent pathway (Li Q. et all., 2011). Injured tubular cells also release Danger 
Associated Molecular Patterns molecules, which next their effects on neighboring tubular 
epithelial cells and inflammatory cells through toll-like receptor to promulgate innate 
immune response by increasing the production of pro-inflammatory mediators and 
recruitment of leukocytes (Anders H.J. et al., 2007). Also, dendritic cells, which as 
antigen-presenting cells derive from the same bone marrow myeloid progenitor as 
macrophages, are abundant in normal kidney interstitium and share the disease 
progression. 
Inflammatory status build up sustained profibrotic cytokine pressure within the local 
microenvironment and primes fibroblasts and tubular cells to undergo phenotypic 
activation or transition of other cell types and to produce a large amount of ECM 
components. 
In the activation phase, the upsurge of profibrotic pressure in the inflamed 
microenvironment inevitably leads to the activation and recruitment of matrix-producing 
cells, known as myofibroblasts (Chuang P.Y. et al. 2013). Many cell types in the 
tubulointerstitium of the kidney, such as fibroblast, tubular epithelial cells, vascular smooth 
muscle cells and a subset of macrophages, are capable of producing ECM, during chronic 
renal injury response cells from five different source contribute to the pool of 
32 
myofibroblasts. These include activation of interstitial fibroblast, differentiation of 
pericytes, circulating fibrocytes recruitment, tubular epithelial cells and endothelial cells 
that undergone to transdifferentiation, acquired a mesenchymal phenotype. (Fig n°2.). 
 
 
 
 
Figure n°2: Origin of scar-associated kidney myofibroblasts. Data  derived from mouse 
kidney fibrosis models support m ultiple cellular origins for αSMA -posit ive interstitial  
myofibroblasts that appear de novo in response to chronic injury  (Eddy AA, 2013) .  
 
 
Renal interstitial fibroblast are commonly regarded as the principal source of matrix 
production, which generate a large amount of interstitial matrix components as fibronectin, 
type I and Type III collagen.  
In the normal Kidney, fibroblast are situated in the interstitium space form a network 
throughout the parenchyma, thereby stabilized the architecture (Kaissling B. et al., 2008). 
While, stellate shaped cells exibhit abundant rough endoplasmic reticulum, collagen-
secreting granules and actin filaments, and express platelet-derive growth factor receptor 
(PDGFR)-β and fibroblast-specific protein (FSP)-1,a small protein that binds calcium and 
is associated with cytoskeleton (Liu Y., 2011).  
Fibroblast activation occurs in response to cytokine cues as: PDGF, TGF-β, fibroblast 
growth factor (FGF)-2, l’insulin-like growth factor (IGF)-1, CTGF, and other factor as 
plasminogen activator (PA)-1 and retain PDGFR-β and FSP-1, in a auto-sustained systems 
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through both the autocrine and paracrine simuli. These promote fibroblast survival, 
increased myofibroblast proliferation activity and up-regulate the protein expression, in 
particular for ECM component, whit new filament types as vimentin, and α-smooth muscle 
actin (α-SMA), (Grande MT et al., 2009), wich leads to expantion of the fibroblast 
population and interstitial space in kidney disease. Despite α-SMA express in a few 
subpopulation of local fibroblast under normal condition and also during a fisiological 
wound-healing response, extensive studies indicate that its abundance is closely correlated 
with the severity of the renal fibrosis and predicts the decline of kidney function (Hewitson 
T.D., 2009). Vascular pericytes represent another relative contribution to myofibroblast 
population into the interstitial fibrosis scenary. Pericytes are a subset of the stromal cells 
that partially cover capillary walls, thereby stabilizing the endothelium. Following renal 
injury, pericytes are detached from the endhotelium, undergo migration into interstitium, 
proliferate, and differentiate into myofibroblasts (Lin S.L. et all., 2008; Humphreys B.D. et 
all., 2010). Probably, pericyte response to same stimuli of fibroblast such as cytokine, as 
evidenced by the presence of PDGFR-β, but more remains to be elucidate (Kaissling B. et 
al. 2008). Further sources of matrix-producing cells are the epithelial-mesenchymal 
transition and the endothelial-mesenchymal transition (EMT and EndoMT respectively), 
(Zeisberg M et al. 2010). EMT is a cells phenotypic conversion process that occur during 
embryonic development, tumor metastasis and organ fibrosis; its characterized by loss of 
epithelial futures and acquisition of mesenchymal markers, under the bombardment of 
various profibrotic cytokines, particularly TGF- β1. TGF- β1/Smad pathway such as ILK, 
Wnt/ β-catenin and Snail1 are all EMT-regulatory signaling that show a preferentially 
activation in renal tubular epithelia after injury(Hewitson T.D et al. 2009; Li Y. et al. 
2009). Tubular cells with mesenchymal future can fully differentiate into interstitial 
myofibroblast  and contribute to ECM production. EndoMT is considered to be a unique 
forma of EMT, as endothelial cells are a specialized type of epithelia of capillary 
endothelium (Li J et al., 2009; Zeisberg E.M., et al., 2008) 
However, the  contribution of EMT to renal fibrosis is controversial (Kriz W et al. 2011; 
Liu Y., 2011). Some studies described a direct involvement for both phenomena (Yang J. 
et al. 2001; Iwano M et al. 2002), other claimed a contrary theses (Humphreys B.D. et al., 
2010; Li L. et al., 2010) 
Assuming that EMT is a dynamic process in which epithelial cells and fibrocytes represent 
two extremes of a continual spectrum of intermediate cell phenotypes, tubular cells 
undergo a partial tansition, in which cells change one or two phenotypic markers, although 
the transitional program is activated. Such as a partial EMT, however, is associated whit 
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poor outcome and predicts the progression toward interstitial fibrosis in humans (Li L. et 
al., 2010; Herting A. et al., 2008). 
Bone-marrow derived cells, known as fibrocytes are a subset of circulating monocytes with 
fibroblast like-future, in the periferal blood. In response to kidney injury, activated 
fibrocytes infiltrate renal parenchyma and participate to fibrogenesis, as shown by some 
studies (Sakai N. et al., 2008; Niedermeier M. et al., 2009).  
Regardless of their different origins of matrix-producing cells, activated 
fibroblast/myofibroblast bring and to being the execution phase of renal fibrosis. 
Characterized by an excessive accumulation and deposition of interstitial matrix and 
formation of collagenous fibers, properly assembled and finally modified to resist 
proteolysis.  
During this phase integrin-associated protein complex constitutes the molecular machinery 
that integrates various fibrogrogenic signal and orchestrates the matrix production and 
assembly. Integrins integrate the “outside-in” and “inside-out” signals between cells and 
their extracellular environment (Margadant C et al. 2010; Legate K.R. et al. 2009). These 
transmit their signal by activating the down-stream effector kinase, focal adhesion kinase 
and ILK. Integrines and their associated proteins constitute the core components of this 
machinery (Legate K.R. et al. 2006). A once, through their respectively receptors and 
specific downstream intracellular-signal cascade, cytokins active a host of transcription 
factor that act on the cognate elements in the promoter same genomic regions. Expression 
and synthesis of the ECM proteins is primarily controlled at gene transcription level in 
response to various “positive” fibrogenic cues. TGF-β1 regulates the expression of major 
components of this complex such as β1-integrin, ILK and PINCH, via Smad signaling 
(Margadant C et al. 2010; Li Y. et al, 2007; Yeh Y.C. et al, 2010; Li Y. et al., 2003). Ang 
II leads to upregulation of the components of this complex, through pathways either 
dependent or independent of TGF-β1(Yang F. et al., 2010; Carvajal G. et al., 2008; Yang 
F. et al., 2009). PDGF, FGF2 and CTGF participate leading to activation of ILK and 
production of matrix components. Such signal transduction cascade and expression of 
matrix gene are also regulate by a variety of microRNAs. While hepatocyte growth factor 
(HGF) and bone-morphogenetic protein (BMP)-7, inibith the production of matrix 
components, primarily antagonizing TGF-β1 (Liu Y. 2004) 
A molecules machinery serves as a platform that integrates diverse fibrogenic signal and 
control of matrix production(Liu Y. 2011). 
In the early stage of renal fibrosis, deposition of fibronectin precedes the production of 
fibrillar collagens of type I and type III, and regulate their assembly. This process is 
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followed by the production of a variety of new matrix proteins, such as secreted protein 
acidic and rich in cysteine (SPARC) and type IV collagen, as well as vimentin,  
vitronectin, thrombospondin, decorin and proteoglycan (Eddy A.A., 2005; Bradshaw A. 
D., et al, 2009). A collagen matrix newly synthesized is susceptible to proteolysis, and 
therefore the fibrosis is potentially reversible, which lead to wound-healing. While, 
biochemical modifications of the matrix proteins by cross-linking are induced by enzyme 
such as tissue transglutaminase and lysyl oxidase, rendering them stiff and resistant to 
proteolysis, (Eddy A.A., 2005). 
Although, the accumulation of matrix protein is a prominent future of fibrosis but not the 
sole factor contributing to the progressive loss of renal function associated with renal 
failure. Many cellular and molecular events beyond the production of matrix components 
determine the reversibility and ultimate outcome of renal fibrogenesis, outlining the 
progression phase. There is a shift from normal wound-healing to over-exuberant 
inflammatory response resulting in the undesirable consequence. 
Sustained lymphocytes and macrophage infiltration, tubular epithelial cells and endothelial 
cells transdifferentiation, also peritubular vasculature rarefaction, tubular cells apoptosis 
and atrophy are present and contribute to the progressive loss of kidney function whit 
fibrotic scarring and renal parenchyma collapse (Zeisberg M et al. 2010; Schlondorff DO, 
2008). 
Damage to tubular epithelial cells induce the activation of major inflammatory and 
fibrogenic signaling such as NFkB, ILK, β-catenin and TGF-β1 pathways, described 
above, also instigates protective and regenerative responses such us autophagy and cell 
proliferation (Li L. et al., 2010). Normally, autophagy and apoptosis are process of “self-
eating” and “cell-death” that mediates adaptation to calorie restriction, hypoxia or in 
inflammatory condition, as a mechanism of cell survival and protection to renal tissue 
omeostasis (Kume S. et al, 2010; Jiang M. et al., 2010). In up-regulate condition could be 
the underling mechanism that leads tubular cells decomposition. Simultaneously, cell 
proliferation is increased but the net mass of epithelial cells is decreased. Presumably 
owing to an increased rate of apoptosis and EMT as result of a defect in the cells cycle 
cause cells switch to a profibrotic phenotype with an increase of TGF-β expression 
(Koesters R et al., 2010; Yang L. et al., 2010). Furthermore, this condition diminish the 
effectiveness of its endogenous protective mechanism as BMP-7 and others antifibrotic 
factors produced by tubular cells in normal kidney (Wang S. et al., 2006), establishing a 
vicious cycle in patients with CKD. Moreover, chronic injury impairs the integrity of the 
tubular basement membrane (TBM) trough a transiently down-regulated of collagen type 
36 
IV, the major component of TBM, and the induction of matrix metalloproteinase (MMP)-2 
and MMP-9 synthesis and action (Yang J. et al., 2002). MMPs are protease able to degrade 
the ECM component, in a normal condition of wound-healing reduce matrix accumulation. 
Although might protect the kidney with antifibrotic action by counterbalance to up-
regulated synthesis in the advanced stage, their activation in the early stage is generally 
pathogenic by impairing of the TBM and faciliting EMT, as demonstrated by different 
study on transgenic mice (Wang X et al., 2010; Cheng S. et al., 2006).  
Additionally, endothelium dysfunction due to activation of myofibroblasts from pericytes 
under EndoMT not only generate more matrix-producing cells but also directly leads to the 
pericytes deficiency and peritubular microvascular rarefaction (Schrimpf C. et al. 2011). It 
cause a reduction in nutrient and oxygen supply and diffusion in the scared tissue, resulting 
a tissue ischemia and hypoxia, already this by damages and excessive ECM production 
(Mimura I. et al., 2010 ). Chronic hypoxia, characteristic of advanced CKD, often coexists 
with increased oxidative stress and generation of ROS, which incites biological 
modification and damages on important macromolecules including proteins, lipids and 
carbohydrates. These modified macromolecules affect various kidney cells as pathogenic 
mediator and trigger renal inflammation and fibrogenic response (D’Agati et al., 2010; 
Negre-Salvayre et al., 2008). Hypoxia can lead to tubular EMT or apoptosis, activate 
resident fibroblast and impaired peritubular capillaries, thereby promoting a cycle of 
kidney injury and progression of renal fibrosis (Gunaratman L. et al, 2009). 
Like the loss of tubules for atrophy, a decrease in the surface area of the peritubular 
capillaries is an histological feature of progressive renal disease that closely correlates to 
loss of kidney function and end-stage of renal disease. The renal fibrotic extension region 
is not only a marker of injury, but also predicts the loss of function and progression of 
damage in the kidney. (Chuang P.Y. et al. 2013)  
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3. Role of Circulating Fibrocytes into Renal Fibrosis 
Renal fibrosis is a hallmark of progressive kidney disease, as the tubulointerstitial fibrosis 
is the principal cause of the renal function  loss after kidney injury. However, the extent of 
renal fibrosis within the kidney is an independent predictor of clinical outcomes (Nath K.A., 
1998). 
The focal point of tissue fibrosis is a unique population of α-SMA-positive myofibroblasts 
that appear de novo in response to injury, after which they synthesize excessive 
quantitative of ECM.  
As described above, the origin of the myofibroblasts is still the subject of intense debate 
(Eddy AA, 2013). However, different reports provide evidence that bone marrow-derived 
fibroblasts (know as circulating fibrocytes) are recruited into the kidney and contribute to 
kidney fibrosis as matrix-producer cells. 
A mismatched kidney transplantation in humans has shown that the proportion of host-
derived SMA-positive cells is approximately 30% in allografts undergoing chronic 
rejection compared with 10% in those without rejection, suggesting a circulating origin for 
these cells and drawing attention to fibrocytes involvement into the kidney injury (Grimm 
PC. et al., 2001). Until now, many researchers have been focused their studies to 
understand the mechanisms involved into the fibrocytes recruitment, but the real biological 
significance of these cells and their pathological role is still unclear.  
One of the first studies using rodent models of renal fibrosis by under ureteral obstraction 
(UUO) has demonstrated that a 15% of bone marrow-derived fibroblasts were present in 
the kidney, 10 days after obstructive injury. Fibrocytes were identified as cells express 
enhanced GFP under the control of the FSP-1 promoter (Iwano M. et al., 2002). 
Moreover, several studies, in same mice model using bone marrow transplantation have 
showed the presence of circulating-derived myofibroblasts into the kidney, in response to 
injury (, Lin F. et al. 2005; Roufosse C et al., 2006; Lin SL. et al. 2008). Same data were 
reported in a other experiment on in vivo models of kidney damage, in which even up to 
>30% of α-SMA-positive fibrocytes were visible into the injury site, 7 days after ischemia-
reperfusion injury (Broekema M. et al., 2007). 
Cells whit fibrocytes futures (CD34+ spindle shaped cells) have been detected in 
tubulointerstitial lesions in patients with glomerulonephritis and these closely correlated with 
interstitial volume of the damage (Okon et al., 2003). Also, analysis of human injury kidney, 
as people with diabetic nephropathy, has been shown the presence of CD45
+
/proCol1
+
 
myofibroblast into the interstitium, which correlated well with the severity of 
tubulointerstitial lesion. In these cases the interstitial fibrosis showed an inverse correlation 
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between the number of fibrocytes and kidney function, at the time of the biopsy. Into the 
same patients, the glucocorticoid therapy induced a significantly decreased during 
convalescent (Sakai N. et al., 2010). 
Recent research report reveal the relative contribution to the myofibroblast pool by 
fibrocytes and other cells that participate to renal fibrosis. Using more than 20 distinct 
mouse models that were genetically engineered. The results revealed that only a 50% of 
active myofibroblasts occur by local tissue fibroblast, the remainder involved bone-marrow 
derived cells and local cells under EMT/EndMT process (LeBleu V.S. et al., 2013). 
Studies on two murine model of UUO renal fibrosis, treated whit chronic infusion of Ang-
II has been suggested that fibrocytes might contribute to fibrosis by an angiotensin II 
receptor type 1 (AT1R) and type 2 (AT2R), dependent pathway. Which both AT1R-
inhibites mice and AT2R-deficient mice showed an increased circulating fibrocytes 
infiltration with concomitant upregulation of pro-collagen type I, than wild-type mice 
(Sakai et al., 2008). Also, pharmacologic inhibition of angiotensin II type 1 receptor 
reduced the degree of renal fibrosis and the number of fibrocytes in the kidney and in the 
bone marrow, confirming that the renin-angiotensin system by Ang-II play significant roles 
in renal fibrosis. 
The same investigators examined whether the contribution of fibrocytes to renal fibrosis 
was dependent on their trafficking to the kidney via CCL21/CCR7 signaling. While, a 
renal fibrosis mice model that showed CD45+ Col I+ circulating fibrocytes, espressing 
CCR7 infiltrated the diseased kidneys. The inhibition of the CCL21/CCR7 signaling using 
a neutralizing antibody reduced the severity of the fibrocyte infiltration, the degree of 
kidney fibrosis (by almost 50%), and the renal expression of TGF-β1 and Coll I with a 
reduced number of CCR2-infiltrated cells, such as in CCR7-nulle mice (Sakai et al., 2006). 
Further, chemokine receptors of homing pathways resulted to be express by circulating 
fibrocytes, including CCR1, CCR2 and CCR5, usually envolved into migration of the 
principal target tissue (Galligan et al., 2013), as welle as CXCL16/CXCR16 system, which 
especially show in kidney injured models (Chen G. et al., 2011) 
Thus, suggest that circulating fibrocytes may to be engaged to the injury site of kidney, by 
many chemokine-pathway, here these differentiate to myofibroblasts and express α-SMA, 
collagens and other ECM components, contributing to renal fibrosis. Which may be 
responsible for chronic persistent inflammation and immunemodulation by both the 
activation and trafficking of macrophages and other leukocytes, such as inducing 
EMT/EndoMT process in resident stromal cell, by MCP1/CCL2 and TGF-β1 expression.  
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Experimental Study  
4. Aims 
Circulating fibrocytes are the mesenchymal precursor of bone marrow origin, present with 
few levels in the peripheral blood of healthy subjects. As described below, different studies 
showed a direct correlation between increased levels of circulating fibrocytes and the 
progression of disease characterized by a fibrotic degeneration as well as in chronic renal 
disease. 
To investigate circulating fibrocytes population futures, in this study, we developed and 
optimized a protocols of whole blood sample collection and enrichment methods of 
PBMCs, also we developed a flow cytometry analysis methods, a gene expression assay 
and a fibrocytes culture assay to detect and characterize the circulating fibrocyte cells. 
These laboratory methods were realized with the finally aim to investigate a correlation 
between the renal fibrosis progression and the different circulating fibrocytes levels, as 
well their activation status, in CKD patients. With these assumptions we proposed to Ethic 
Committee an observational (case/control) study protocol to provide the evidence that the 
evaluation of activated circulating fibrocytes levels measurements might be a new 
biomarker to monitoring the activity and progression of fibrogenesis into a CKD patients, 
as well in early phases. 
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5. Materials and Methods 
5.1. Samples 
Human peripheral blood was collected by venipunture from eight healthy adult volunteers, 
four for both sexes and with written consent, for a total volume of about 18 ml by each 
subject. A Ficoll-Paque system, Lymphosep (Biowest), was used to separate a poor sample 
of peripheral blood monocytes cells (PBMCs) from whole blood. Blood sample was 
diluted in phosphate-buffered saline (PBS) 1X with a ratio of 1:2 and transferred into a 
conical tube with ficoll medium pre-loaded.. It’s system was improved with the 
implementation of the Leucosep tube (Greiner Bio-One, North America Inc.), a porous 
barrier incorporated into the tube that enables PBMCs isolations. Leucosep tube prefilled 
with separation medium, thanks to the barrier, prevents mixture of the sample material 
with the ficoll or a recontamination of the enriched cell fraction. After a centrifugation for 
15 minutes at 1000 x g at real temperature (RT), lymphocytes and PBMCs are separated 
from whole blood, on the basis of their density, and enriched in an inter-phase above the 
separation medium. PBMCs fraction was harvested and washed twice with 10ml of PBS1X 
and centrifugated for 10 min at 250 x g at RT, to eliminate the platelets. An incubation 
with ACK lyses solution for 3-4 min on ice was developed to clean the samples rich for 
erythrocytes cells.  
Commercial cell lines as HEK293T, Jurkat, and HT29 cell line (ATCC), were used to test 
the sensibility and specificity of the antibody, for antigen not highly expressed by PBMCs, 
which were selected to perform the flow cytometry analysis. 
These tests samples were used to perform the preliminary experiments of flow cytometry 
analysis, differentiating cultures and molecular assays. It was necessary to develop a 
protocol analysis for the characterization and study of circulating fibrocytes, in CKD 
patients.  
Subsequently we will develop an investigation of circulating fibrocytes in sixth patients 
affected by CKD, divided in four distinct groups based on GFR levels, and thirty subjects 
no affect (control group), will be expected between the patients afferent to the U.O. of  
Nefrology, Dialisis e Trasplantation of Prof. S. Stefoni, in the Policlinico S. Orsola-
Malpighi Hospital of Bologna. 
 
Group A: 20 patients affects by CKD with estimated Glomerular Filtration Rate (eGFR*) 
comprise between 30 and 45 mL/min/1.73 m² . 
Group B: 20 patients affects by CKD with eGFR comprise between 15 e 30 mL/min/1.73 m². 
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Group C: 20 patients affects by CKD with eGFR < 15 mL/min/1.73 m². 
Group D: 30 subjects not affect by any type of chronic renal disease with eGFR > 90 mL/min/1.73 
m².(control group) 
Patients and healthy controls samples will be collected during outpatients visit, by the 
selection futures described above. Subsequently, these will be transferred to the Bioscience 
Laboratory of IRST for the processing and experimental analysis. These will be analyzed 
into the bioscience laboratory of “Istituto Romagnolo per lo studio e la cura dei tumori” 
(I.R.T.S.), of Meldola (FC). 
 
5.2.  Sample collection systems  
As described, circulating fibrocytes precursor are rear. Their detection is difficult and false 
positive results are easy. Different storage protocols were tested to preserve the sample, 
from the time of collection to the analysis. Blood samples were tested for all storage and 
analysis methods used in this study, it was necessary to develop and validate a sensitive 
and specific protocols. Two different collection tube systems were tested: BD Vacutainer® 
Blood Collection Tubes, for 9 ml, containing the anty-coaugulant EDTA (BD Bioscience, 
San Jose, CA) and CytoChex tubes, 9ml, containing a cell fixation solution and EDTA 
(Cyto Chex® BTD, Streck U.S.). The EDTA-tube system was selected because necessary 
to mRNA extraction and cells differentiation culture assays, while CytoChex as direct-
draw blood collection tube specifically to immunophenotyping by flow cytometry.  
 
5.3. Enrichment methods 
Enrichment methods were tested to increase and improve the circulating fibrocytes 
detection than the total cell populations of the peripheral blood. the of the fibrocytes 
population. In this study we tried two cells enrichment methods, based on 
immunomagnetic separation systems, with monoclonal antibody directed to a specific 
antigen of interest, conjugated with paramagnetic beads. MACS CD34 human MicroBeads 
kit for magnetic labeling of cells associated to the MACS Large Cell Separation (LS) 
Columns (Miltenyi Biotec Gmbhy, Germany) and the EasySep™ magnet with the 
EasySep™ Human whole blood CD34 Positive Selection Kit (StemCell Technologies 
Inc.). Both the immmunomagnetic separation systems are based on a positive selection for 
CD34 positive cells, as marker of human hematopoietic stem and progenitor cells. These 
provides two work steps: an incubation phase whit anti-CD34 monoclonal antibody, 
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conjugated with the paramagnetic beads and a subsequently enrichment phase through the 
use of magnetic devices. In the first method,  the samples labelled with CD34 magnetic 
conjugated monoclonal antibody, incubated for 30 min at 2-8°C, cells were loaded in a pre-
balanced column placed in the MiniMACS separation Unit. The CD34
+
 cells are 
magnetically labelled to the columns, while the negative fraction discarded as effluents. 
After, it’s important to wash the columns for 2-3 times with 500µl of PBS 1X 
supplemented with 2mM EDTA and 0,5% of bovine serum albumin (BSA), namely as 
running buffer, to eliminate any non-specific cell. LS column are removed from separator 
and transferred onto a new collection tube, with 1ml of buffer to the reservoir to the 
column and using the plunger, supplied in the kit, positive fraction were recovered. 
Otherwhise, EasySep™ system consist to a positive cells selection and/or negative cells 
depletionof the sample trough a three-step procedure, as described by the manufacture 
instruction for buffy coat sample. First, the buffy coat samples were incubated with a 
human CD34 monoclonal antibody (clone QBEnd10), for 15min at RT, it followed by 
incubation whit magnetic nanoparticles directed to the Fc portion of CD34 antibody, for 
10min at RT, in EasySep RBC Lysis Buffer solution provided by the kit for both step. 
Which samples were transferred in tube without cup into the EasySep™ magnet and 
incubated for 10 minutes. So, the magnet and tube were inverted to pouring off the 
supernatant fraction with CD34 negatively fraction cells, while the magnetically labelled 
cells remained inside the tube. It step was repeated for 2-3 times whit samples 
resuspension in RBC lysis buffer, to improve the result. Finally, the sample tubes were 
removed by magnet to recover the enriched CD34 positive cell fractions in PBS 1X. 
 
5.4. Cytometry analysis  
Cytometry analysis, in a fist phase, were performed to evaluate the efficiency of the 
collection sample and enrichment phases. Which was important to assessment the 
effectiveness of the Cyto-Chex tube to retain the entire futures of the sample. Also, a 
cytometry method was developed to quantify the percentage of fibrocytes population of the 
blood, in both control and patient samples. 
The PBMCs fraction, pre-fixed by Cyto-Chex tube, were washed in PBS 1X, centrifugated 
and resuspended in RBM buffer. Otherwise samples collected with BD Vacutainer tube 
were fixed using fixation buffer of the Cytofix/Cytoperm kit (BD Bioscience, San Jose, 
CA), following the manufactory instructions. After fixation, samples were wash in PBS 
1X, centrifugated and resuspended in RBM buffer (Miltenyi). Also 1*10
6 
cells of each cell 
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lines describe above were used as positive control to test sensibility and specificity of each 
antibody to develop the fibrocytes measurement method. HEK293T were used to test the 
anti-Collagen Type I-FITC, clone 5D8-G9 (Milli-Mark®, Millipore), Jurkat cell line were 
used for anti-CXCR4-PE, rat anti-human, clone 2B11 (eBioscience), and HT29 cell line with 
anti-CCR7-APC, mouse anti-human, clone 3D12 (BD Pharmingen™). Positive control cell 
lines were treated whit same procedures describe here. While, antibody anti-CD45, CD34 
and CD11b were tested directly on PBMCs samples. 
2*10
6
 cells of PBMCs and 1*10
6
 cells of CD34 positive cell fractions by both collection 
systems, were aliquoted to each tube for flow cytometry and processed to extracellular 
antibody stained. Cells were incubated with anti-CD45, PerCP-Cy 5.5, mouse anti-human, 
clone 104 (BD Pharmingen™), anti-CD34-PE-Cy7, mouse anti-human, clone 8G12 (BD), 
anti-CXCR4-PE, rat anti-human, clone 2B11 (eBioscience) and anti-CCR7-APC, mouse 
anti-human, clone 3D12 (BD Pharmingen™), in RBM buffer, for 15 min at 4°C. 
Intracellular staining was performed after cell permeabilization with Perm/Wash buffer, by 
Cytofix/Cytoperm kit (BD Bioscience, San Jose, CA), for 15min at RT and incubation with 
anti-Collagen Type I-FITC, clone 5D8-G9 (Milli-Mark®, Millipore), for 30min at 4°C. 
Cells incubated with irrelevant isotype-matched antibodies and unstained cells were used 
as controls. After, cells were washd in PBS 1X and trafered in 4 ml FACS tube. 
Fluorescence data were acquired on a FACSCanto flow cytometer (BD Bioscience, San 
Jose, CA) and there were analysed using BD FACSDiva software. 
 
5.5. Cell cultures and in vitro differentiation assay 
Mononuclear cells fraction obtained by whole blood collected in BD Vacutaner tube was 
carefully collected and rinsed twice with PBS 1X. PBMCs were suspended in DMEM 
supplemented with 10% of FBS, 1% penicillin/streptomycin solution and 2mM L-
glutamine and seeded in cells culture flask (CorningTM) at density of 1*10
6
 cells/ml and 
incubated for 24h at 37°C with 5%CO2. After 24h the non adherent cells were removed, 
while the adherent cells, rich in monocytes cells, were collected and rinced twince with 
PBS 1X. 1*10 cells were collected to RNA extraction, the remainder cell fraction was re-
plated at a density of 2.5*10
5
 cells/ml in DMEM serum-free supplemented with 2mM L-
glutammine, 10mM HEPES (Sigma-Aldrich), 1% sodium pyruvate, 1% 
penicillin/streptomycin solution and ITS-3 (Sigma-Aldrich), as recommended by 
previously description (Pilling et al. 2003; Quan TE et al. 2007). These were seeded until 
13 days in two different culture systems.  classical plastic culture dishes 35mmX10mm, 
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and 8 cm
2
 of diameter (Corning
®
) and µ-Dish
 35mm
 Grid-500 ibiTreat, (Ibidi
®
), a tissue 
culture dish 35mm Ø and a grid repeat with a distance of 500 µm. 
Fibrocytes were measured ,at the end of differentiation treatment, by cell count, under x20 
magnifications microscopy, into µ-Dish
 35mm
 Grid-500. Also, cell cultures in normal 
culture dish were monitored and collected to the RNA extraction. 
While, HEK293T Jurkat , and HT29 commercial cell lines were cultured as described by 
ATCC instructions. 
 
5.6. Gene expression assays  
Total mRNA was isolated in three different phases. First 1*10
6
 peripheral blood monocyte 
cells from no-fixed sample tube, immediately after the enrichment phase; second from 
adherent cells after 24h of culture and finally after among two weeks (13 days) of culture. 
RNA was extracted with TRIZOL reagent (Invitrogen), following the manufactory 
instructions. After quantification by Nanodrop instrument, 1µg of total RNA was reverse 
transcribed into first strand cDNA with random primers and M-MLV reverse transcriptase, 
contained into DyNAmo cDNA Syntesis kit (Thermo Scientific). Real-time quantitative 
PCR (RT-qPCR) was performed used FastStart Universal Probe Master, normalization 
with ROX , and Taq-man assays Universal ProbeLibrary Probes selected by ProbeFinder 
assay design software (Roche). Detection and analysis were performed on an Abi Prism 
7500 system (Applied Biosystems). Result of gene expression analysis was expressed as 
fold increase over the value of the control sample, by 2
-ΔΔCt
 analysis method. The 
expression of target genes as collagen I (Coll I), α-smooth muscle actin (α-SMA), CXCR4 
and CCR7 was normalized to 18s transcript. Primer sequences are described in table n°3. 
 
Gene Primer Forward Primer Reverse 
Coll I GCCTCTGCTCCCTTCTCAC CTCTCCTGTTGCGTTGCTC 
α-SMA CCTATCCCCGGGACTAAGAC AGGCAGTGCTGTCCTCTTCT 
FN1 GCGAGAGTGCCCCTACTACA GTTGGTGAATCGCAGGTCA 
CXCR4 GGATATAATGAAGTCACTATGGGAAAA GGGCACAAGAGAATTAATGTAGAAT 
CCR7 GCACAATCTGGTTCTGATGTTC GAGACGCTGTTGGGAACTTT 
18s GCAATTATTCCCCATGAACG GGGACTTAATCAACGCAAGC 
 
Tabel n°3: primers sequences for RT-qPCR to evaluate the gene expression of collagen I (coll I), 
alpha-smooth muscle actin (α-SMA), fibronectin (FN1), C-X-C chemochine receptor 4 
(CXCR4) and C-C chemochine receptor 7 
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5.7. Statistical analysis  
Data were expressed in mean ± SEM (standard error of the mean) unless otherwise stated. 
Graphpad 5.0 was used to perform the statistical analysis. Comparisons were evaluated by 
Student’s unpaired t test. Results were considered statistically significant if p values were 
less than 0.05.  
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6. Results  
Different storage systems  were tested to assess the preservation of the sample futures at 
the moment of the blood collection, without sample alteration or degradation. Cytometry 
analysis of PBMCs collected with Cyto-Chex system (pre-fixation) showed no different 
results respect to no fixing system collection, as EDTA-tube (BD tube), for both samples 
obtained by same healthy volunteers. Cells processed and analysed by flow cytometry 
didn’t showed different physical parameters or variation for expression levels of principal 
cells markers as CD45, CD3 and CD34 (Fig n°3). 
 
Figure n°3: Comparison between  BD Vacutainer® Blood Collection  Tubes,  (A to D) and 
CytoChex tubes (E to H). Flow cytometric dot plot of physical parameters of PBMCs (A 
and E) and immunophenotype analysis for some principal extracellular markers CD45, 
CD3 and CD34, for both treatment protocols of sample .  These don’t show significant 
futures changes.  
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6.1. Enrichment protocols  
With the final aim to obtain an high concentration of circulating fibrocytes we tried to 
integrate the standard protocol with an enrichment phase after the PBMCs extraction. To 
improve the fibrocytes detection, two different enrichment methods were tested. The two 
systems: MACS CD34 human MicroBeads kit and EasySep™ Human whole blood CD34 
Positive Selection Kit used and tested in this study are based on immunomagnetic CD34
+
 
cells selection. Both immunomagnetic selection systems showed an effective in enriching 
cellular fraction CD34
+
 but not sufficient to fibrocytes analysis. Samples processed to such 
enrichment showed an excessive reduction in the cell numbers, not enough to perform a 
good flow cytometric analysis (data not show). 
 
6.2. Circulating fibrocytes detection by flow cytometry analysis  
Antibodies used to developed the circulating fibrocytes measurement by flow cytometry 
were tested on positive control cell line and on PBMCs samples, for each marker. Isotype-
matched antibodies controls were tested on same samples.  
Results of each single antibodies showed a specific interaction with the corresponding 
antigen, also these didn’t show a positive or detectable signal for isotype-matched 
antibodies tests (data not show). Thanks to this preliminary test, it was possible to define 
unique conditions, as time and temperature, for sample treatment and antibody staining 
protocols, for both extracellular and intracellular antigens. 
In this develop phase of the study we tested and measurement the percentage of circulating 
fibrocytes expressed to the PBMCs population by flow cytometry using 4 markers to 
discriminate the circulating fibrocytes population (CD45, CD34, CD11b and Coll I), while 
CXCR4 and CCR7 were used to discriminate and evaluate the activation status of these 
circulating precursors(Fig n°4). 
Preliminary results on the first eight healthy adult volunteers, , showed the identification of 
the circulating fibrocytes in the total white blood cells (WBC) sample, to confirm the 
specificity and sensibility of the cytometry analysis method developed. In healthy control, 
the percentage of fibrocytes relative to normal percentage of white blood cells (WBC) as 
CD45
+
 resulted very low or absent, with a low presence of fibrocytes into the 1*10
5
total 
number of cells analyzed (0.04±0.01%),. 
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Figure n°4: Flow cytometric  analysis of c irculating fibrocy tes in PBMCs, by healthy donor. 
Physical distribution of PBMCs (A), Monocytes cells posit ive to CD45 and CD34  (B).  
CD11b expression of CD34
+
/CD45
+
(C). Collagene I expression of CD34
+
 cells, as 
precursors (D) and CD45
+
 to identify Circulating Fibrocytes (E). Fibrocytes cells 
posit ive for CXCR4 (F ).  
 
6.3. Cell cultures and cell count differentiated fibrocytes 
Into PBMCs cultures in conditional medium, we observed that after 13 weeks a portion of 
cells were differentiated into fibrocytes. These cells appear adherent and with a spindle-
shaped morphology (Fig. n° 5). The number of fibrocytes were counted into the repeated 
grid of the ibiTreat culture dish, under x20 magnification. Their percentage reflected the 
flow cytometry data analysis, relatively to the total number of PBMCs seeded (among 
2.5*10
5
cells). 
 
6.4. Gene Expression analysis of principal fibrocyte markers 
Total mRNA extracted by 1*10
6
 cells of total PBMCs sample and by total adherent cells in 
culture were collected after 24h and at the end of the 14 days of the conditioning cultures, 
for each healthy volunteers sample.  
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Gene expression of collagene I, α-SMA and fibronectin was quantified for adherent cells 
after 24h and 13 days of conditional culture plate. Results showed a significantly 
upregulation of fibrocytes markers in the samples cultured for 13 days, it compared to 24h 
PBMCs cultures (p<0.05), for the same donor sample. CXCR4 gene expression results  
showed a lower and unchanged levels between the different culture time samples. CCR7, 
however, resulted very weakly/not expressed in these samples (Fig.n°5).  
 
 
 
Figure n°5: Fibrocytes differentiation from PBMCs cultures (A). Cells with spindle -shaped 
cells, as fibroblast -like cells, are visible after 14 days of culture, by black arrows 
alighted (B). Gene expression levels of principal f ibrocytes markers analyzed 24h and 
14 days after seeding (C,D and E). Marker expression of CCR7 and CXCR4,  as markers 
of f ibrocytes activation (F and G); (* p<0.05).  
  
* * 
* 
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7. Discussion 
Circulating fibrocytes (CFs) are bone marrow-derived mesenchymal cells showing 
haematopoietic and progenitor cell markers (CD45, CD11b, CD34), which comprise only a 
small fraction of circulating leucocytes in healthy humans, comprise between 0.1-0.5% of 
them (Quan TE et al., 2006). However, an increase in CFs number is observed in human 
pathologies, characterized by chronic inflammation and persisted fibroblast activation, 
coupled with ECM production. A large body of evidence has shown that circulating 
fibrocytes might play a role in kidney fibrosis, contributing to the myofibroblast 
incensement (among 35%) (LeBleu VS et al., 2013). This is supported by both in vivo and 
in vitro evidence. 
In this study, we optimized a protocol for whole blood sample collection and for the 
enrichment of the PBMCs fraction. Moreover, we set-up a flow cytometry assay for the 
detection and the characterization of circulating fibrocyte cells. Using fibrocytes culture 
assays and gene expression assays we improved and confirmed the CFs analysis method.  
Cyto-Chex  storage tube (Cyto Chex® BTD, Streck U.S.) were tested as collection system 
to store the sample, from the time of collection to the analysis. It is essential to preserve the 
cells futures of a rear and plastics cell population as circulating fibrocytes. Flow cytometry 
analysis on samples colleted with Cyto-Chex tube were compared to results with classical 
EDTA-tube. Both tube systems showed same result, without loss or alteration of the 
samples (Fig. n°3). While EDTA tube system was used, in this preliminary phase, because 
necessary to the cells differentiation culture assays and also to the mRNA extraction for the 
gene expression assays. 
Fibrocytes are a minimal portion of circulating monocytes cells of the blood. Samples 
collected by healthy volunteers were processed for a PBMCs extraction by ficoll-paque 
system Lymphosep (Biowest), it improve with the Leucosep centrifugation tube (Greiner 
Bio-One, North America Inc.), specific to the mononuclear cells extraction by blood.  
Due to the rarity of fibrocytes populations, we tested two method for the enrichment of 
CD34
+
 cells fraction. PBMCs extracted by the whole blood samples were processed to 
both these immunomagnetic systems and then analyzed by flow cytometry. Cytometric 
analysis on CD34
+
 cells from the blood led to good levels of enrichment, with an increase 
of the precursor cells into the sample. However, the CD34 antigen result expressed by a 
minimal fraction of cells than the total monocytes cell populations of the peripheral blood, 
among them are included fibrocytes. Though these samples appeared with a CD34
+
 cells 
enrichment, these didn’t improved the fibrocytes detection with a possible risk to reduce 
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the number of fibrocyte too. Probably the few start levels of the fibrocytes into the whole 
blood and the possible poor expretion of CD34 by CFs, represents a limit to obtain a 
sample rich for CD34
+
 cells.  
Circulating Fibrocytes express markers characteristic of hematopoietic cells, as CD45 and 
CD34, and monocytes marker as CD11b; they are unique in that they also produce 
extracellular matrix (ECM) protein as pro-collagen/collagen type I (Ishii G et al., 2005). 
Altogether, these futures represent the principal markers that allow identifying fibrocyte 
cells in a heterogeneous sample such as whole blood or fibrotic tissue. Furthermore, these 
cells express the chemokine receptors CCR2, CCR3, CCR5, CCR7 and CXCR4 (Mehrad 
et al., 2007; Wada et al., 2011), which are essential to the bone-marrow cell homing as 
well as during the recruitment into the inflammatory site. In particular, CCR7and CXCR4 
chemokines axes are involved into kidney fibrosis (Sakai N. et al., 2010) 
Bearing in mind this evidence, we developed and improved a common flow cytometry 
method for the identification of fibrocytes population. Antibodies labelled with 
fluorochromes directed against the principal fibrocytes markers (CD45, CD34, CD11b, 
pro-Coll/Coll I) were selected and tested for the detection of CFs. Also, antibody direct to 
the chemokine receptors CCR7 and CXCR4 were chosen and implemented in order to 
detect the circulating activated form of fibrocytes cells. 
Positive control tests performed using cell lines, expressing a specific antigen for each 
antibody allowed to confirm the validity of the procedure and to define the optimal setting. 
Specially they allowed to define unique conditions, time and temperature, for sample 
treatment and antibody stained protocols, for both extracellular and intracellular antigens 
selected to the flow cytometry analysis of CFs. Subsequently, this method was employed 
for the preliminary quantification tests of fibrocytes amount in eight healthy volunteers (4 
men and 4 women). The relative percentage of CFs in the total PBMCs sample obtained 
were in accordance with the literature (0.04±0.01%), of this analysis method. 
Previous studies report that fibrocytes can be obtained after 1-2 weeks of differentiating 
culture of PBMCs in vitro. These data suggest that there is heterogeneity with respect to 
the ability of monocytes to differentiate in culture, specially between healthy and patients, 
with a higher possibility in the non healthy subjects. Moreover, as describe in literature, 
adding conditioned medium from PBMCs with a high yield of fibrocytes into PBMCs with 
a low yield of fibrocytes did not increase fibrocytes number, indicating that the number 
fibrocytes developed by PBMCs in some individuals may be due to the intrinsic property 
of their monocytes (Pilling D. et al. 2009). These monocytes may be “preprogrammed” to 
adopt the fibrocytes phenotype, perhaps through genetic or epigenetic changes in 
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progenitor cells, rather than relying purely on external influence. However, other studies 
confirm a direct influence of some factors as TGF-β or specific pathological condition on 
fibrocytes activation and differentiation (LeBLeu V.S. et al., 2013). By demonstrating the 
correlation between the activated circulating fibrocytes number with an increased collagen 
production, into a pathological condition, some study suggest a link between fibrocytes 
number and morbidity of the disease (Galligan C.S. et al., 2012). Probably, in patients, it 
does not influence the number of CFs but it affects the level of activated fibrocytes. 
We have prepared PBMCs cultures by each healthy donors sample to observe if and how 
many monocytes differentiated into fibrocytes. After culturing adherent PBMCs for 13 
days, we found the appearance of adherent spindle-shaped cells with ovoidal nucleus, as 
well typical fibroblast-like futures of fibrocytes. These were counted and the result 
confirmed the flow cytometry data (in %), compared to the total cells seeded. Conditional 
fibrocytes culture were employed to the gene expression assays (Fig.n°5).  
Previous study demonstrated that the expression level of factors as collagen, fibronectin, 
vimentin and other CFs markers were enhanced in fibrocytes differentiated in culture 
(Pilling D. et al., 2009). In the present study, gene expression levels of principal fibrocytes 
markers like collagene I, α-SMA and fibronectin, were quantified for adherent cells in 
conditional culture plate. After 13 days of culture these were significantly upregulated 
compared with the same donor sample, after only 24h of culture assay (Fig n°5). However, 
CXCR4 gene expression results showed a lower and unchanged levels between the 
different culture time samples, while CCR7 resulted not expressed in these samples (data 
not show). 
Thanks to the laboratory methods developed in this study it was possible to carry out a 
study of circulating fibrocytes in patients with chronic kidney disease. With these 
assumptions we proposed to Ethic Committee an observational (case/control) study 
protocol, namely “FCFR”, to investigate the role of CFs in kidney fibrosis progression into 
CKD patients. Sixty patients affected by CKD, divided in three distinct groups based on 
GFR levels, and thirty subjects not affected as control group are being recruitment. 
Experiments of flow cytometry analysis, in vivo culture assay and gene expression will 
evaluate to role of CFs in renal fibrosis of CKD pathogenesis. 
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8. Conclusion and futures  
A flow cytometry approach coupled with in vitro culture assay and gene expression 
profiling was developed to study and characterize the CFs population, in the peripheral 
blood of healthy subjects. Preliminary results confirm that these method of analysis allow 
reliable and reproducible investigation of the fibrocytes cells fraction in whole blood 
sample. 
Further studies using these method are ongoing, to dissect the relation between the 
progression of renal fibrosis  and the different circulating fibrocytes levels in CKD 
patients, as recently suggested by previous studies (Sakai N. et al., 2010; LeBleu V.S. et 
al., 2013). The renal fibrotic extension region is not only a marker of injury, but it also 
predicts the loss of tissue function and the progression of the damage in the kidney. 
(Chuang P.Y. et al. 2013).  
The finally aim of this study will be provide the evidence that the evaluation of activated 
circulating fibrocytes levels measurements might be a new biomarker to monitoring the 
activity and progression of renal fibrosis in CKD, as well in early phases of the disease. 
Further studies aimed at understanding the biology of circulating fibrocytes, as well novel 
laboratory methods that allows to detect CFs with a greater sensitivity and lower costs, will 
be crucial for understanding the implication of CFs in the CKD pathology and to improve 
the diagnostic and prognostic methods used until now. 
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